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CHAPTER I 
 
INTRODUCTION 
 
The Prostate 
 
The prostate structure 
 The prostate gland is a part of the mammalian male reproductive system 
about the size of walnut, which is located just in front of the rectum and below the 
bladder. The prostate consists of many small exocrine glands that produce fluid 
portion of semen, which contains important secretory proteins and helps the 
motility of the sperm. The prostate is divided into several compartments, i.e. 
lobes (Hutch, 1972; Lowsley, 1912) or zones (McNeal, 1968; McNeal, 1972; 
McNeal, 1978; McNeal, 1980; McNeal, 1981). According to McNeal, the prostate 
is divided into four compartments. First, the peripheral zone (PZ) occupies more 
than 70% of the glandular prostate and the majority of prostate cancers arise 
from this area. The peripheral zone is close to the rectum since it is located in the 
back of the prostate gland, and its ducts radiate laterally from the urethra and are 
lateral and distal to the verumontanum. Second, the central zone (CZ) constitutes 
~25% of the glandular prostate and its ducts branch proximally to the ejaculatory 
duct, and the lateral branches lie parallel to the proximal branches of the 
peripheral zone. Third, the urethral transition zone (TZ) is located around the 
urethra and proximally to the base of the verumontanum. It is the primary area 
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where benign prostatic hyperplasia (BPH) develops. Fourth, the anterior 
fibromuscular stroma is entirely non-glandular and makes up about 1/3 of the 
prostate volume within the prostatic capsule (Figure 1). 
 
 
 
 
 
 
 
 
 
Figure 1. The zonal structure of the human prostate (Sagittal view). The 
prostate is mainly composed of 4 subdivisions: peripheral zone, central zone, 
transition zone and anterior non-glandular fibromuscular stroma. 
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The prostate development 
 Embryologically, the prostate derives from the urogenital sinus (UGS) 
which is endodermal, unlike the mesodermal derivation of most other male 
accessory sex glands (Prins, 2008). The binding of 5α-dihydrotestosterone (DHT) 
to the androgen receptor (AR) in mesenchymal tissue induces the prostatic buds 
from the UGS to initiate outgrowth (Shannon, 1983; Takeda, 1991; Takeda, 
1985). The outgrowth of the buds undergoes extensive branching 
morphogenesis at the fetal stage. After birth, androgens affect lumen formation of 
the ducts and the epithelium starts to differentiate and synthesize secretory 
products (Timms, 2008) (Figure 2). However, full maturation of the prostate 
occurs at puberty. 
 
 
 
 
 
 
 
 
Figure 2. The stages of the prostate development. [Adapted from (Prins, 
2008)] 
 3
Hormonal and genetic regulation of prostate development 
 During the fetal stage, androgens produced from the fetal testes regulate 
prostatic development. A series of studies using rodent animal models 
demonstrated that surgical/chemical castration during particular periods of fetal 
life inhibits prostate development (Cunha, 1973; Jost, 1953; Lasnitzki, 1977; 
Price, 1936; Price, 1961). Upon androgen ablation in ex vivo organ culture, 
however, the mouse/rat UGS retrieved at the time when fetal testes produce 
testosterone formed prostatic buds but did not form buds before testosterone 
production (Cunha, 1973; Lasnitzki, 1977), which suggests that the timing of 
androgen ablation is thought to be critical when the prostatic bud formation 
initiates. Also, DHT which more actively binds to AR induces prostatic budding 
more efficiently than its parental compound, testosterone, which implies that the 
entire dependence of prostate development is on hormonal (androgen) regulation 
with androgen receptor signaling at fetal stage. Hormonal action of androgen is 
mediated by interacting with AR and inducing transcriptional activity of AR. 
 In addition to the hormonal regulation with androgen receptor signaling, 
some candidate genes are also believed to regulate morphogenesis in prostate 
development either by each individual gene itself or by cross-talk among them. 
They are categorized into (1) nuclear transcription factors including homeobox 
genes and (2) secreted signaling molecules that act through paracrine/autocrine 
signaling between epithelial and mesenchymal cells (Hogan, 1999). As shown in 
Table 1, Hox genes are known to determine body patterning from invertebrates 
(fruit fly) to vertebrates (humans) (Krumlauf, 1994), and Nkx3.1 has critical roles 
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in prostate branching morphogenesis and differentiation (Bhatia-Gaur, 1999; 
Schneider, 2000; Tanaka, 2000). Transcription factors like Forkhead box genes 
(Fox) including Fox A1/A2 are thought to be involved in ductal morphogenesis, 
epithelial cell maturation and bud initiation (Kopachik, 1998; Mirosevich, 2005). 
Also, Notch signaling pathway determines cell fate and patterning in tissue 
development (Bolós, 2007), as it inhibits expansion of prostatic progenitor cells 
and helps differentiation of epithelial cells during prostate development (Grishina, 
2005; Shou, 2001; Wang, 2006; Wang, 2004). Furthermore, paracrine or 
autocrine factors such as Hedgehogs, Fgfs, Bmps/Tgfβ/Activins and Wnt 
signaling regulators and their associated receptors mediate signals between 
epithelial and mesenchymal cells. 
 
 
 
Table 1. Genes involved in the prostatic development 
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Cell types within prostatic ducts 
 Within human prostatic ducts, epithelial cells can be classified into at least 
3 cell types. They are morphologically and functionally distinct, and are 
composed of secretory luminal cells, basal cells present between luminal cells 
and basement membrane, and neuroendocrine cells which are very rare and 
express various neuropeptides (Figure 3). Luminal cells are the most 
predominant, are androgen-dependent, and uniquely produce prostatic secretory 
proteins. They are distinguished by the expression of the androgen receptor (AR), 
cytokeratin 8 and 18 and surface marker CD57 (Brawer, 1985; Liu, 1997; Nagle, 
1987; Sherwood, 1990; Verhagen, 1988). The second major epithelial cells are 
basal cells that express cytokeratin 5 and 14, CD44 and low levels of AR (still 
controversial) (Brawer, 1985; Bui, 1998; Liu, 1997; Nagle, 1987; Sherwood, 
1990; Verhagen, 1988). Prostatic stem cells are believed to present as a 
subpopulation of basal cells which are androgen-independent (Bonkhoff, 1996; 
De Marzo, 1998). Third, androgen-independent neuroendocrine cells constitute a 
minor portion of the prostatic epithelium and are mostly distributed in the basal 
layer. They are thought to be involved in providing paracrine signals that facilitate 
the growth of luminal epithelial cells but their embryological origin is not clear. 
They express distinct factors like serotonin, chromogranin A and neuropeptides 
(Abrahamsson, 1999; di Sant’Agnese, 1992; di Sant’Agnese, 1998).  
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Figure 3. Cell types within a human prostatic duct. Prostatic epithelial cells 
are composed of luminal, basal and neuroendocrine cells which are very rarely 
present. 
 
 
 
 
 
Stem cells in the prostate 
 The existence of prostate stem cells in the basal cell layer was 
hypothesized from the observation that basal cells preferentially survived upon 
androgen ablation (Isaacs, 1987). p63 (basal cell-specific marker) deficient mice 
were born without a prostate (Signoretti, 2000) and secretory prostate cells 
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originated from p63+ basal progenitor cells in the chimeric blastocysts consisting 
of p63- and p63+ cells during development (Signoretti, 2005). Recently, prostate-
regenerating cells in the proximal region of mouse prostate were enriched using 
Sca-1, a cell surface marker, although Sca-1+ cells in the distal region or even 
Sca-1- cells were observed to regenerate prostatic cells (Xin, 2005). In the 
human prostate, stem cells were isolated using α2β1 integrin (Collins, 2001; 
Hudson, 2000) and CD133 (Richardson, 2004). α2β1hi/CD133+ cells were 
randomly found all over the prostatic acini/ducts (Collins, 2001; Richardson, 
2004) and at the base of budding areas or branching tips. Moreover, cells that 
were morphologically and phenotypically intermediate between basal and luminal 
epithelial cells were identified within normal epithelium (Brandes, 1966; Mao, 
1966; Sherwood, 1990; van Leenders, 2000; Verhagen, 1992), which suggested 
possible hierarchical relationship between two cell types that are derived from the 
same origin. 
 In general, stem cells are quiescent and localized in a specific area called 
a niche. The microenvironment in the niche is known to support the stem cells to 
be balanced between quiescence and self-renewal (Lang, 2009). In human adult 
prostate, epithelial stem cells were shown to exist at the basement membrane 
with high expression of α2β1 integrin (Collins, 2001). β1 integrins are known to 
maintain stem cell functions and promote asymmetric division of mammary stem 
cells (Taddei, 2008). Inductive mesenchymal signal is reported to control 
epithelial cell differentiation during prostate development with the help of 
androgen signaling (Cunha, 1989). This is further supported by the finding that 
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rodent prostatic mesenchyme could regulate the generation of prostatic epithelial 
tissues from human embryonic stem cells (Barclay, 2008; Taylor, 2006). 
 
Prostate cancer statistics and risk factors 
 Prostate cancer is the most commonly diagnosed cancer and the second 
largest cause of cancer deaths in American men. The American Cancer Society 
(ASC) estimates that nearly 192,280 new cases will be diagnosed, and 27,360 
men will die of prostate cancer in the US during 2009 (www.cancer.org). 
Although certain links to prostate cancer are not clear, several risk factors are 
reported to significantly contribute to prostate cancer, including age, region, race, 
family history, steroid hormone, life style, and infection and inflammation of the 
prostate (www.cancer.org) (Fleshner, 2009; Fradet, 2009). Age is the most 
significant factor for prostate cancer. The disease incidence dramatically 
increases for men of 50 or older, and two out of every three prostate cancer 
cases are found in men over the age of 65. The incidence of prostate cancer in 
some regions like North America and northwestern Europe is known to be much 
higher than Asian countries. Moreover, prostate cancer is more common in 
African-American men than in men of other races. Although hereditary prostate 
cancer cases are relatively rare, certain inherited mutations are known to 
increase prostate cancer risk and cause prostate cancer from generation to 
generation in some families. Mutations in BRCA2, for example, seem to raise the 
risk up to 20 times (Edwards, 2003), and multiple chromosome loci on 8q24 are 
also reported to be important loci that could increase prostate cancer risk (Cheng, 
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2008). In addition to prostate development, signaling between steroid hormones 
and their receptors is also known to play an important role in prostate 
tumorigenicity, so hormonal changes, i.e. androgen/estrogen in men, can alter 
incidence of prostate cancer. Studies have shown that obesity increases the risk 
of prostate cancer, so life styles, such as diet and exercise, are also believed to 
be important. Furthermore, infection and inflammation of the prostate gland might 
affect the risk, although the link is still controversial (www.cancer.org) (Klein, 
2008; Sutcliffe, 2008). 
 
Molecular genetics of prostate cancer 
 Prostate cancer is thought to arise from accumulated genetic mutations 
that may transform benign prostatic epithelium to prostatic intraepithelial 
neoplasia (PIN), a precursor of prostate cancer. PIN displays four characteristic 
structural patterns, i.e. tufting, micropapillary, cribriform, and flat (Bostwick, 1996; 
Bostwick, 1999; Bostwick, 1993; Bostwick, 1987; Nagle, 1991). This stage is sub-
categorized into low grade PIN (LGPIN) and high grade PIN (HGPIN), and the 
latter is believed to be an immediate precursor of early invasive carcinoma. Both 
PIN and early prostatic carcinoma commonly display reduction of E-cadherin and 
vimentin which are an adhesion protein and a cytoskeletal component, 
respectively. Invasive carcinoma exhibits discontinuous basement membrane 
due to microinvasion of transformed epithelial cells into stroma. PIN lesions, 
however, display complete glandual structure with intact and continuous 
basement membrane (Bostwick, 1993). With additional genetic alterations, PIN 
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progresses to invasive cancer, and finally to metastatic disease (Figure 4). 
Metastatic prostate cancer is generally accompanied by emergence of androgen-
independency, marked by failure to respond to androgen ablation therapy. 
 It has been observed that distinct chromosomal loci including 6q, 7q, 8p, 
10q, 13q, 16q, 17p and 18q are deleted in human prostate cancer specimens at 
different stages of prostate cancer progression, although individual deletion 
frequencies vary and more characterization is still needed (Figure 4) (Cooney 
and Wojno, 1996; Cunningham, 1996; Elo, 1997; Latil, 1994; Latil, 1997; Saric, 
1999; Takahashi, 1995; Zenklusen, 1994). According to allelic loss on the 
chromosome locations, some tumor suppressor genes such as NKX3.1, PTEN, 
RB and p53, are potential candidate genes (Figure 4). In addition to candidate 
tumor suppressor genes, various cancer-related genes contribute to prostate 
cancer progression at each stage (Abate-Shen, 2000; Tomlins, 2006), i.e. 
initiation from normal prostate, progression to early carcinoma, and development 
to metastatic disease (Table 2).  
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Figure 4. Multi-step model of prostate cancer progression. Distinct loci on 
the chromosomes are frequently deleted during human prostate cancer 
progression. 
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Table 2. Candidate genes dysregulated in prostate cancer progression 
 
Genes Function 
Initiation (Normal to PIN) 
NKX3.1 Homeodomain transcription factor 
Progression to carcinoma 
MYC, MXI1 Transcription factors 
PTEN Phosphatase 
RB, p27 and p16 Cell cycle regulators 
Telomerase Reverse transcriptase 
FGFs Growth factors 
E-cadherin, c-CAM, Integrins Cell adhesion/interaction 
c-MET Tyrosine kinase receptor 
Advanced carcinoma and metastatic disease 
AR Nuclear hormone receptor 
p53 Transcription factor/Apoptotic regulator 
BCL2 Apoptotic regulator 
IGF1, TGFα, TGFb1, EGF Growth factors 
KA1 Membrane protein 
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C-Myc 
 
Gene and protein structure of c-Myc 
 c-Myc is an oncogenic, basic helix-loop-helix transcription factor. c-Myc 
was first identified as a homologue of viral oncogene v-Myc of avian 
myelocytomatosis virus MC29 (Vennstrom, 1982). N-Myc and L-Myc are also 
members of Myc proto-oncogene family whose sequences were found amplified 
in neuroblastoma and small cell lung cancer, respectively (Nau, 1985; Schwab, 
1983). These three Myc genes have been the most intensively studied (Table 3). 
c-Myc gene is composed of three exons and it encodes a short, predominant 
protein product, c-Myc 2, and long form, c-Myc 1, which is translated from 
alternative translation initiation site, CTG on the exon 1 (Figure 5A). The 
expression levels of the long form c-Myc 1 are generally low, but induced to 
levels comparable to short form when in vitro cultured cells are highly confluent 
(Hann, 1992). The function of c-Myc 1 seems to be contradictory because it was 
shown to inhibit in vitro cell growth unlike short form (Hann, 1994) but further 
investigations are needed to characterize differential functions between short and 
long form c-Myc. c-Myc protein is basically composed of two domains. First, MYC 
box I and II (MBI and MBII) at the N-terminus of c-Myc are required for the 
transactivation of target gene expression. Second, basic helix-loop-helix leucine-
zipper (bHLH-Z) domain at C-terminus is a crucial region for binding of c-Myc to 
a conserved DNA sequence such as E-BOX (CACGTG) for transactivation 
(Blackwood, 1991) (Figure 5B).  
 14
 
 
 
 
 
 
 
 
 
 
Table 3. Mammalian Myc family genes 
 
Myc genes Functions 
c-Myc Cellular transformation 
Apoptosis 
Cell cycle progression 
L-Myc 
N-Myc 
Cellular transformation 
Cell cycle progression 
S-Myc Growth suppression 
Apoptosis 
B-Myc Inhibition of neoplastic transformation 
P-Myc/L-Myc Ψ Pseudogenes 
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 (A) 
 
 (B) 
 
 
Figure 5. Schematic depiction of human c-MYC gene and its protein 
products. Long form of c-MYC protein (c-MYC 1) is initiated from alternative 
translation site (CTG) (A). (B) describes MYC boxes (MB I & II), nuclear 
localization signal (NLS), basic region (B), helix-loop-helix (HLH) and leucine-
zipper (LZ) on c-MYC protein. NTD, CTD and TAD stand for N-terminal domain, 
C-terminal domain and transactivation domain, respectively. Numbers indicate 
amino acids. 
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Transcription regulation by c-Myc 
 There are multiple molecules that interact with c-Myc and they activate or 
repress transcription activity as transcriptional coregulators (Figure 6). To 
activate target gene transcription, c-Myc binds to the E-BOX sequence after 
forming a heterodimer with another basic helix-loop-helix leucine-zipper protein 
MAX (Solomon, 1993) and sometimes coactivators such as Pim-1 kinase (Zippo, 
2007) and TRRAP (McMahon, 1998) with its associated HATs (histone acetyl 
transferases, GCN5 or Tip60) (Frank, 2003; Frank, 2001; McMahon, 2000) 
(Figure 6B). On the other hand, MIZ-1, a zinc-finger transcription factor, binds to 
c-Myc-MAX heterodimer and this interaction is believed to be important for 
repressing transcriptional activity of c-Myc, although the mechanism of 
repression is still not clear (Herold, 2002; Kime, 2002; Seoane, 2002; Seoane, 
2001; Staller, 2001; van de Wetering, 2002; Wu, 2003) (Figure 6C). Table 4 
shows selected target genes either induced or repressed by c-Myc, and their 
functions (Adhikary, 2005). 
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Figure 6. c-Myc binding proteins and transcription activation/repression by 
c-Myc with coregulators. (A) Representative c-Myc-interacting molecules and 
their binding sites on c-Myc. (B) and (C) describe transcription activation and 
repression by c-Myc and its coregulators, respectively. 
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Table 4. Selected c-Myc target genes and their functions 
 
Target genes Regulation Functions 
ODC, RCL, 
HMGI/Y, PMTA 
UP Anchorage-independent growth 
Transformation (rat fibroblast) 
HDAC2 UP Suppression of differentiation 
CCND1, 
CCND2, CDK4 
UP G1 progression upon mitogen stimulation 
Proliferation, carcinogenesis 
E2F2 UP c-Myc-induced proliferation  
LDHA UP c-Myc-induced transformation 
SHMT UP c-Myc-induced proliferation and growth 
IRP2 
H-ferritin 
UP 
DOWN 
c-Myc-induced proliferation and transformation 
p21CIP1 DOWN Cell cycle checkpoint 
Cell differentiation 
p15INK4B DOWN TGF-β-mediated proliferation arrest  
N-cadherin, 
integrins 
DOWN Adhesion of stem cells to stem cell niche 
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Biological functions of c-Myc 
 c-Myc has multiple roles in regulating biological phenotypes including cell 
proliferation, apoptosis, transformation, and inhibition of differentiation (Figure 7). 
 
 Cell proliferation and cell growth 
 One of the most crucial functions of c-Myc is that it promotes cell 
proliferation by cell-cycle progression. In quiescent cells in vitro, c-Myc levels are 
not detectable, but the expression levels of c-Myc mRNA and protein are 
dramatically increased when cells are stimulated with mitogens or serum (Amati, 
2001; Amati, 1998; Dang, 1999; Eilers, 1999). In c-Myc-deficient rat fibroblast 
cells, cell proliferation is dramatically suppressed and cells show cell-cycle 
defects in the G1 phase (Mateyak, 1997). In addition, homozygous c-Myc 
deletion in mice in vivo leads to embryonic lethality (Davis, 1993), suggesting an 
important role of c-Myc in regulating normal growth during embryonic 
development (Davis, 1993). 
 Cell-cycle in G1-S progression of eukaryotic cells is controlled by the 
complexes of cyclins and CDKs (cyclin-dependent kinases), i.e. cyclin D-CDK4 
and cyclin E-CDK2, and c-Myc regulates G1-S progression by activating or 
repressing target genes involved in cell-cycle progression. In fact, c-Myc is 
known to directly activate the expression of CCND2 (cyclin D2) and CDK4 
(Bouchard, 1999; Coller, 2000; Hermeking, 2000) or recruit HATs associated with 
TRRAP indirectly to change chromatin structure and enhance the accessibility of 
c-Myc-MAX complex to the DNA sequence (Figure 6) (Bouchard, 2001). Also, c-
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Myc inhibits cell-cycle arrest by repressing the expression of cell-cycle arrest 
genes such as CDK inhibitors (e.g. p15INK4b) (Staller, 2001) and p21WAF1/CIP1 
(Herold, 2002). 
 In addition to cell proliferation, dMyc (Drosophila orthologue of c-Myc) is 
reported to control cell size in the wing imaginal disc during fly development, 
although cell-cycle distribution was not affected upon diminished dMyc levels 
(Johnston, 1999). When c-Myc was activated in p27-deficient mouse embryonic 
fibroblasts (MEFs), cell growth was stimulated without affecting cyclin E-CDK2 
activity (Beier, 2000). In P493-6 cells, a human B cell line, c-Myc induced cell 
growth in the absence of cell division (Schuhmacher, 1999). Moreover, Eu-Myc 
transgenic mice, which are engineered to overexpress c-Myc in the B 
lymphocytes, also displayed elevated cell growth (Iritani, 1999; Pelengaris, 
2002a). Evidence demonstrates that c-Myc increased cell size without affecting 
proliferation through cell-cycling. 
 
 Inhibition of cell differentiation 
 There seems no doubt that c-Myc inhibits cell differentiation because cell-
cycle progression and terminal differentiation are generally incompatible each 
other. However, c-Myc is reported to block cell differentiation regardless of 
promoting cell proliferation (La Rocca, 1994; Ryan, 1997). Some studies on the 
crypts of the GI (gastrointestinal) system and epithelium of the skin demonstrated 
that c-Myc expression was observed in proliferating cells while MAD protein 
expression was restricted in differentiating cells where c-Myc was undetectable 
 21
(Chin, 1995; Hurlin, 1995a; Hurlin, 1995b). It is not clear whether downregulated 
c-Myc caused cell differentiation or the former was just one of the consequences 
of the latter. However, studies demonstrated that c-Myc, MAX and MAD family 
transcriptional repressors, which include MAD1, MXI1, MAD3 and MAD4, were 
believed to be involved in regulating terminal differentiation (Foley, 1999; 
Grandori, 2000). Moreover, MAX dimerized with MAD and this dimer competed 
with c-Myc-MAX complex by binding to E-BOX. Also, MAX-MAD recruited 
HDACs (histone deacetylases) to E-BOX where MAX-MAD bound and repressed 
c-Myc target gene expression by decreasing the accessibility of transcription 
factors following local chromatin modification (Ayer, 1995; Schreiber-Agus, 1995). 
In vivo evidence showing that a knockout mouse model of Mad1 exhibited altered 
differentiation of granulocytes supported the role c-Myc in cell differentiation 
(Foley, 1999). 
 
 Cell apoptosis 
 Some oncoproteins such as c-Myc and E1A are known to enhance cell 
proliferation as well as apoptosis (Askew, 1991; Debbas, 1993; Evan, 1992). 
Although contradictory, cell proliferation index and apoptotic rate increased 
simultaneously when transformed cells expanded. Although cellular context such 
as cell types, tissue location, and presence of additional mutations affect the 
machinery of c-Myc-induced apoptosis, increasing evidence demonstrates a 
strong link between c-Myc and apoptosis. When rat fibroblasts with c-Myc 
overexpression were cultured under low serum, cells completely underwent 
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apoptosis (Evan, 1992). c-Myc is also known to sensitize cells to pro-apoptotic 
stimuli such as hypoxia, DNA damage through ROS (reactive oxygen species) 
induction, limited survival factors (Askew, 1991; Evan, 1992) and apoptotic 
signaling pathways (Hueber, 1997; Klefstrom, 1994; Lutz, 1998). Furthermore, c-
Myc is involved more directly in apoptosis by inducing cytochrome c release from 
mitochondria into cytoplasm, which is an initial stage of general apoptotic 
pathway (Juin, 1999). c-Myc expression is important for activating BAX through a 
conformational change that induces cytochrome c release, and it is tightly 
controlled by the presence of other anti-apoptotic molecules, e.g. BCL2, BCL-XL, 
or other survival factors (Brenner, 2000; Eskes, 1998; Green, 2002; Juin, 1999; 
Soucie, 2001). Additionally, c-Myc activates p19ARF expression, an inhibitor of 
MDM2 (E3 ligase), resulting in p53 stabilization, so is thought to contribute p53-
dependent apoptosis (Zindy, 1998). It is also observed in Eu-Myc transgenic 
mice in vivo (Jacobs, 1999). 
 
 Cellular transformation 
 Data suggest that c-Myc induces cellular proliferation or transformation by 
regulating cell-cycle and metabolic pathways. First, cyclin D-CDK4 complex is 
believed to have an important role in c-Myc-induced transformation since cyclin 
D1/D2/D3-deficient fibroblasts were not transformed by c-Myc overexpression 
(Kozar, 2004) and CDK4-deficiency significantly repressed tumorigenic activity of 
c-Myc in epithelial tissues (Miliani de Marval, 2004). Second, c-Myc is known to 
enhance glucose uptake and glycolysis through target gene activation involved in 
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glucose metabolic pathways, such as lactate dehydrogenase A (LDHA) (Dang, 
1999; Shim, 1997) (Table 4). When LDHA gene expression was deficient in the 
fibroblasts, c-Myc-induced transformation was inhibited (Shim, 1997). C-Myc also 
controls iron metabolism by inducing the expression of the transferrin receptor 
and iron responsive element binding protein 2 (IRP2), and repressing the 
expression of H-ferritin and NRAMP1. Both increased available iron levels in the 
cytosol (Bowen, 2002; Wu, 1999). Although the mechanism is not known, re-
expression of H-ferritin blocked c-Myc-induced transformation by sequestering 
iron (Wu, 1999) (Table 4). Third, metabolic enzymes required for folate 
metabolism were upregulated by c-Myc and promoted cell growth and 
proliferation. Induction of one of these enzymes in c-Myc-null fibroblasts partially 
mimicked c-Myc effects in that both cyclin D and CDK4 were expressed 
(Nikiforov, 2002). 
 It is very rare that deregulated c-Myc alone transforms normal cells to 
tumorigenic cells, and therefore cells with enhanced c-Myc levels need additional 
mutation(s) to be fully transformed. Since c-Myc induces cell proliferation as well 
as apoptosis that limits cellular transformation, deletion of barrier genes such as 
p19ARF, p53 (Eischen, 1999) or BIM (Egle, 2004), or overexpression of 
oncogenes, e.g. BMI-1 (Jacobs, 1999) and TBX-2 (Jacobs, 2000) that repress 
p19ARF expression or anti-apoptotic BCL-XL (Egle, 2004; Pelengaris, 2002b), 
facilitated c-Myc-induced tumorigenesis. 
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 Other functions 
 Numerous studies have demonstrated that high levels of c-Myc 
expression induce DNA damage, which is partly promoted by ROS. When c-Myc 
was activated, ROS was elevated in both tissue culture and in vivo system 
(Reimann, 2007; Vafa, 2002), which was probably due to disruption in 
mitochondrial biogenesis (Dang, 2005; Li, 2005; Morrish, 2003) or cellular 
metabolism (Ray, 2006; Tanaka, 2002). In addition, c-Myc was reported to 
promote DNA replication independently of transcriptional activity (Dominguez-
Sola, 2007), which may also cause DNA damage. Moreover, c-Myc induced 
translation regardless of transcriptional activity by activating mRNA capping, i.e. 
methylation of 5’ mRNA guanine, a critical step for gene translation from mRNA 
(Bentley, 2005; Cowling, 2007; Shatkin, 1976; Shuman, 2002). 
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Figure 7. Biological functions of c-Myc. c-Myc induces cellular proliferation, 
growth, apoptosis, transformation, gene translation, and DNA damage. Also c-
Myc inhibits terminal differentiation. 
 
 
 
 
 
C-Myc and cell competition 
 Cell competition is the phenomenon that when there is(are) certain 
mutation(s) in a subset of the cells in the cell population, cells become “super-
competitors” by actively eliminating neighboring “loser” cells which do not have 
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that mutation(s). In contrast, defective mutated cells (losers) are killed by 
neighboring intact cells (winners). This phenomenon was observed in wing 
imaginal discs during Drosophila development and dMyc (Drosophila homologue 
of Myc) was thought to be involved in a gene dose-dependent manner. Mutant 
cells with only one copy of dMyc gene were eliminated in the presence of wild 
type cells with intact two copies of dMyc. In addition, cells with three copies of 
dMyc became “super-competitors” by outcompeting wild type cells and were also 
outcompeted by cells with four copies of dMyc (de la Cova, 2004; Moreno, 2004). 
Interestingly, similar phenomenon was observed in mammals, although more 
investigations are needed to examine and determine cell competition. In the 
mouse intestine with conditional c-Myc deletion, the number of c-Myc-deficient 
cells per crypt was dramatically reduced compared to c-Myc-proficient wild type 
cells in the same c-Myc-deficient animals (Muncan V, 2006). Several pathways 
have been proposed to explain cell competition, but the mechanism is not still 
conclusive. One cell culture study recently showed that some unknown soluble 
factors released from high-dMyc cells may possibly contribute to kill low-dMyc 
cells (Senoo-Matsuda, 2007). 
 
C-Myc and human prostate cancer 
c-Myc is known to be overexpressed in many human cancers including 
prostate cancer. Its expression is often deregulated by copy number amplification, 
chromosomal translocations, proviral insertion and retroviral transduction (Marcu, 
1992) but many tumors still display c-Myc activation by other unclear 
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mechanisms. Resuls showing that chromosomal locus (8q24) where c-MYC is 
present was somatically amplified in some prostate cancer patients (Jenkins, 
1997; Nesbit, 1999; Qian, 1997; Sato, 1999), suggested that c-Myc may be 
involved in prostate cancer progression. Also c-MYC amplification showed 
significant correlation with higher pathological grades and a worse disease 
prognosis (Jenkins, 1997; Sato, 1999). Numerous studies have confirmed that 
mRNA levels of c-MYC were elevated in human prostate cancer samples, 
compared to benign prostate tissues (Buttyan, 1987; Dhanasekaran, 2005; 
Fleming, 1956; Lapointe, 2004; Meng, 2002; Tomlins, 2007; Varambally, 2005; 
Yu, 2004). Recently, Gurel et al. analyzed “functional” nuclear c-MYC protein 
expression levels as a transcription factor (Persson, 1984) in human prostate 
specimens in contrast to cytoplasmic c-MYC detection done in most previous 
papers, and showed that c-MYC protein was overexpressed in 76% of PIN, 
81.6% of adenocarcinoma and 68% of metastatic prostate cancer (Gurel, 2008). 
These data suggest that c-MYC alteration is one of the early events in human 
prostate carcinogenesis. 
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Pten 
 
 Pten, Phosphatase and tensin homologue, is a phosphatase that has the 
function of tumor suppressor. Human PTEN gene is located on the chromosome 
10 and this chromosomal locus is known to be frequently deleted in many human 
cancers, including prostate, breast, lung, and bladder cancer (Simpson, 2001). 
During tumorigenesis, however, Pten expression is reduced or completely 
deficient either by somatic gene deletion or epigenetic mechanism, including 
promoter methylation (Sansal, 2004). In addition to somatic mutation in PTEN, 
germline mutation in Pten is known to cause Bannayan-Zonana syndrome, 
Cowden’s syndrome and Lhermitte-Duclos disease (Liaw, 1997). 
 Pten protein is a phosphatase that dephosphorylates phosphate group at 
3-position of inositol ring and its most important substrate is phosphoinositol tri-
phosphate (PI(3,4,5)P3 or PIP3) (shown below). In many tumors, Pten deficiency 
results in hyperactivation of Akt, which is prosurvival/anti-apoptotic because PIP3 
phosphorylated by phosphoinositol 3 kinase (PI3K) activates the downstream 
target protein kinase B (Akt) family (Sun, 2001). 
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 Pten plays a critical role as a tumor suppressor because Pten is a unique 
protein phosphatase that no other enzymes can replace (Li, 2007). Also, Pten 
has close a relationship with cancer-related molecules and pathways, such as 
p53 and Akt. Akt is known to decrease cyclin-dependent kinase (CDK) inhibitor 
p27kip1 which controls G1 arrest, and leads to cell-cycle progression from G1 to S 
(Sherr, 1999; Slingerland, 2000). In addition, Akt inactivates Bad, a pro-apoptoic 
protein by phosphorylation, so cells are prevented from apoptosis (Datta, 1999; 
Datta, 1997). 
 In addition to Akt, Pten is also connected to the c-Jun N-terminal kinase 
(Jnk) pathway, and Jnk is thought to be activated through BMP signaling with 
Pten deficiency. When Pten was deleted in mice in a prostate-specific manner, 
BMP7 was upregulated (Yang, 2005), and BMP7 induced Jnk activity in C4-2B 
cells, a PTEN-null human prostate cancer cell line (Yang, 2006). Also, Jnk is 
activated in Pten-null cells and human prostate cancer specimens with active 
AKT or PTEN-deficiency (Vivanco, 2007).  
 Pten interacts with p53 in many ways. p53 is known to regulate Pten 
transcription (Stambolic, 2001) and Pten protects p53 from degradation that 
occurs through mdm2-mediated ubiquitinylation by forming a complex with p53 
(Freeman, 2003a; Mayo, 2002; Zhou, 2003). 
 Pten is also thought to control genomic stability. When Pten is deficient, 
activated Akt induces mono-ubiquitination of DNA damage checkpoint kinase 1 
(Chk1) by phosphorylating serine 280 (Puc, 2005a). This results in an impaired 
response to DNA damage. Additionally, Pten loss was reported to decrease 
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Rad51, a DNA repair protein, so that double-stranded DNA breaks (DSB) were 
elevated and caused genomic instability (Puc, 2005b). 
 Fluorescence in situ hybridization (FISH) studies demonstrated that PTEN 
(both heterozygous and homozygous) deletion occurs frequently in human 
prostate cancers. Yoshimoto et al. (Yoshimoto, 2006) showed that PTEN deletion 
was observed in 23% of PIN and 68% of prostate cancer without metastasis. Han 
et al. (Han, 2009) also reported that 9% of HGPIN, 17% of primary cancer, and 
53% of metastatic disease displayed PTEN deletion. Collectively, the data 
indicate that PTEN loss is a late event in human prostate carcinogenesis 
compared to c-Myc overexpression. 
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CHAPTER II 
 
MOUSE AS A MODEL ORGANISM 
 
Introduction 
 
 To examine gene functions and their roles in human diseases in vivo, 
investigations have used several animal models such as nematodes 
(Caenorhabditis elegans), flies (Drosophila), frogs (Xenopus) and rodents (rats 
and mice). Among the frequently used model organisms mentioned above, 
humans and mice were the most recently diverged (evolutionarily around 75 
million years ago), and there have been only 0.01 changes in gene structure per 
gene despite the process of evolution in each lineage (Mouse Genome 
Sequencing Consortium, 2002). In addition to genetic similarity, there are other 
multiple advantages of mice as an in vivo model organism for basic and cancer 
biology. First, mice are among the smallest mammals, so they are easy to handle 
and take care of. Second, their generation time is reasonably short and females 
have large litters (5 to 10), so they are a good model system for genetics. Third, 
they display high tumor incidence and relatively fast tumor growth, which 
additionally makes mice valuable model for cancer biology. 
 For prostate cancer research in particular, mice are useful because they 
show functional and structural similarities in the prostate to that of humans 
(Figure 8). The peripheral zone (PZ) in human prostate which occupies about 
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70% of the glandular prostate is comparable to the dorso-lateral lobe in mouse 
prostate. In addition, the human central zone (CZ) is comparable to the mouse 
anterior lobe. However, there are no homologous counterparts of the human 
transition zone (TZ) and mouse ventral lobe in mouse and human prostate, 
respectively (Ahmad, 2008). However this similarity is based on descriptive data, 
so molecular characterization of each compartment needs to be assessed for 
further comparisons. Also, mice do not spontaneously get prostate cancer but 
they can get cancer that is histologically similar to human prostate cancer with 
genetic or chemical manipulation. 
 
 
 
 
 
Figure 8. Comparison of human and mouse prostate structure. A and B 
describe human and mouse adult prostate structure, respectively. AP, DP, LP 
and VP in (B) stand for anterior, dorsal, lateral and ventral prostate, repectively. 
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Current Mouse Models of Prostate Cancer 
[This part is adapted from {Abdulkadir, S.A. and Kim, J., Future Oncology 
(2005)}] 
 
There has been substantial progress made recently in the effort to model 
human prostate cancer in mice. Several mutant mice have been generated which 
mimic various aspects of the human disease, including the development of 
preneoplastic lesions, invasive carcinoma, and metastases. These mouse 
reagents provide the research community with valuable new tools for dissecting 
the mechanisms of tumorigenesis, as well as for testing new targeted therapies. 
Although rodents do not spontaneously develop prostate cancer, recent 
advances in murine modeling of human cancer have provided the scientific 
community with new tools for investigating the mechanisms of prostate 
carcinogenesis, as well as parameters in response to chemoprevention and 
therapy. Nonetheless, there is a need for refining the current models to address 
scientific questions that may not be easily examined in vitro or in human subjects. 
For the generation of transgenic murine models of prostate cancer, the choice of 
promoter used to target transgene expression is of paramount importance. The 
temporal and spatial pattern of transgene expression, which may be cell-specific, 
is driven by a promoter that causes dramatic effects on the resulting phenotype.  
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Models that develop prostatic epithelial hyperplasia/dysplasia/PIN without 
progression to carcinoma 
 
Several models have been generated that develop prostatic epithelial 
hyperplasia/dysplasia/PIN without evidence of progression to invasive carcinoma 
over the course of the lifetime of the organism. These have mostly been models 
in which a single gene is disrupted or overexpressed in the prostatic epithelium. 
These results indicate that multiple pathways may have to be disrupted for 
progression to invasive carcinoma.  
 
Nkx3.1 mutant mice 
Nkx3.1 encodes a homeodomain transcription factor whose expression is 
androgen-dependent and largely restricted to the luminal epithelial cells of the 
prostate (Bieberich, 1996). Reduced NKX3.1 protein expression has been 
observed in approximately 75% of human prostate tumors and 20% of PIN 
lesions (Bowen, 2000). Mice lacking Nkx3.1 develop prostatic epithelial 
hyperplasia that progresses to PIN over time (Abdulkadir, 2002; Bhatia-Gaur, 
1999). Mice with conditional deletion of Nkx3.1 in the mature prostate also 
develop hyperplasia and PIN (Abdulkadir, 2002). The latter finding is consistent 
with the loss of NKX3.1 expression observed in human PIN lesions, since the 
PIN lesions in the conditional knockout mice arise independent of the prostate 
developmental defects observed in regular Nkx3.1-knockout animals. Epithelial 
hyperplasia seen in Nkx3.1-/- and Nkx3.1+/--mutant mice may be a consequence 
of an extended proliferative phase due to a delay in exiting the cell cycle by 
differentiating luminal epithelial cells (Magee, 2003). Gene expression analysis of 
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Nkx3.1 mutant mice revealed a class of dosage-sensitive Nkx3.1 target genes 
that demonstrate a stochastic, on/off pattern of expression. Thus, a reduction in 
Nkx3.1 dosage reduced the proportion of cells expressing this class of target 
genes. These findings are consistent with a model of haploinsufficient tumor 
suppression in which reduction in Nkx3.1 dosage increases the probability of 
complete loss of expression of select target genes in luminal epithelial cells.  
 
Probasin-androgen receptor transgenic mice 
The androgen receptor (AR) plays an important role in the normal 
development of the prostate as well as in all stages of prostate carcinogenesis 
including androgen-independent disease. Expression of the wild-type AR 
transgene under the control of the rat Probasin promoter (Pb) resulted in 
increased cell growth and PIN, and provides a model system of AR-stimulated 
PIN that can be used for assessing preventative hormonal therapies and for 
identifying secondary transforming events relevant to human prostate cancer 
(Han, 2005; Stanbrough, 2001). While expression of wild-type AR does not lead 
to prostate cancer, prostate-specific expression of a mutant AR (AR-E231G) has 
recently been demonstrated to lead to the development of metastatic prostate 
cancer (Han, 2005). 
 
Probasin-AKT transgenic mice 
Inactivating somatic mutations of PTEN or loss of the PTEN protein are 
common in prostate cancer cell lines and tumors. Mutations in PTEN lead to 
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deregulated phosphoinositide-3 kinase (PI3K) signaling, resulting in constitutive 
activation of downstream targets such as the protein kinase B (Akt) kinase family 
(Sun, 2001). Sellers and colleagues have generated mice expressing active Akt 
in the prostate (murine prostate Akt kinase transgenic [MPAKT] mice) (Majumder, 
2003). In these mice, Akt expression led to p70S6K activation, and PIN. Thus, 
the MPAKT model may be a useful model to study the roles of Akt in prostate 
epithelial cell transformation and to test new pathway-targeted therapies.  
 
C(3)1-Myc and Probasin-MYC transgenic mice 
Mice with low levels of c-Myc expression in the prostate (C(3)1-Myc) 
develop prostatic hyperplasia and PIN without progression to invasive carcinoma, 
although higher level expression of Myc using the Probasin promoter (in Pb-Myc 
and ARR2Pb-Myc mice) leads to invasive carcinoma demonstrating the 
significance of the dose of an oncogene in prostate tumor progression (Ellwood-
Yen, 2003; Zhang, 2000b).  
 
Probasin-Ras transgenic mice 
While the involvement of Ras in human prostate cancer has not been 
evaluated extensively, activating mutations in H-, K-, or N-Ras have been 
reported in 5–30% of human prostate cancers (Castrillon, 2001). To assess the 
role of Ras in prostate carcinogenesis, a constitutively activated form of H-Ras 
was targeted to the prostate using the minimal Pb promoter. The Pb-Ras 
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transgenic mice present with neoplastic changes in their prostates including low 
grade PIN and intestinal metaplasia (Scherl, 2004).  
 
Retinoid X receptor mutant mice 
Retinoids play an important role in development, differentiation and tissue 
homeostasis (Chambon, 1996). Expression of retinoid X receptor (RXR)α in the 
nucleus is generally decreased in prostate cancer cell lines and specimens, and 
prostate cancer cells in which RXRα is overexpressed demonstrates significantly 
increased apoptosis (Pandey, 2003; Zhong, 2003). Conditional deletion of RXRα 
in the prostate led to the development of hyperplasia and PIN which worsens 
with age, although invasive cancer did not develop. The heterozygous mutant 
mice also developed similar prostatic phenotypes but in a delayed manner, 
implying a role of haploinsufficiency (Huang, 2002). 
 
Retinoblastoma mutant mice 
The retinoblastoma (Rb) tumor suppressor functions in the control of 
cellular proliferation and differentiation (Kranenburg, 1995; Weinberg, 1995). Rb 
gene alterations can occur in all grades and stages of prostate cancer, in 
localized as well as metastatic disease (Brooks, 1995). In human prostate cancer, 
Rb gene mutations have been reported in approximately 16% of primary human 
prostatic cancers (Bookstein, 1990; Kubota, 1995). Conditional deletion of Rb in 
the prostate, however, resulted only in PIN lesions, without development of frank 
carcinoma (Maddison, 2004; Zhou, 2006). It is remarkable that the lesions in 
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these animals did not progress to carcinoma, considering the significant role Rb 
plays in regulating the cell cycle and the fact that it is targeted in human tumors. 
One possible explanation is compensation by other Rb family members such as 
p130, which is expressed at high levels in the mouse prostate.  
 
Fibroblast growth factors mutant mice 
The fibroblast growth factor (FGFs) family of heparin-binding growth 
factors plays important roles in normal prostate development and tumorigenesis 
(Basilico, 1992; McKeehan, 1998). The prostatic epithelial and stromal cells 
express various kinds of FGF ligands and their receptors (FGFR) to transduce 
signals which are required for biologic processes such as branching 
morphogenesis, differentiation and survival (Cunha, 1992). While some of the 
FGFs are overexpressed (Heer, 2004; Ozen, 2001; Polnaszek, 2003; Ropiquet, 
2000), others are downregulated in human prostate cancer cells (Mydlo, 1988). 
Transgenic mice expressing FGF-2 under the control of a short rat Probasin 
promoter were established. When these infertile FGF-2-expressing transgenic 
founder mice were sacrificed for histologic analysis, they demonstrated a simple 
epithelial hyperplasia in the dorsal lobe of the prostate (Konno-Takahashi, 2004). 
However, FGF-2 does have a role in tumor progression as deletion of one or 
both copies of FGF in transgenic mouse model of prostate cancer (TRAMP) mice 
resulted in increased survival, decrease in metastasis, and inhibition of 
progression to the poorly differentiated phenotype in primary prostatic tumors 
 39
(Polnaszek, 2003). Like the situation with FGF-2, expression of FGF7, 3 or 8b in 
the prostate, resulted in hyperplasia and PIN (Chua, 2002; Foster, 2002).  
 
FGF receptors mutant mice 
Models based on the FGFRs mirror the phenotypes of mice expressing 
FGF ligands. FGFR1 and 2 present different functions. FGFR1 activation in 
transgenic mice triggers hyperplasia and PIN while FGFR2 did not demonstrate 
observable changes in prostate (Freeman, 2003b; Jin, 2003; Roy-Burman, 2004). 
The expression of a truncated FGFR23b receptor also caused disorganized 
prostatic ducts that were not tightly associated with the basement membrane as 
well as disorganization of the stroma (Foster, 2002). While none of the models 
based on dysregulation of the FGF receptors or ligands resulted in invasive 
carcinoma, this does not exclude the possibility that these molecules do have a 
role in the later stages of tumor progression. 
 
Skp2 transgenic mice 
An ubiquitin E3 ligase, Skp2, has been implicated in ubiquitinating the 
CDK inhibitor p27kip1 and the transcriptional factor E2F-1. Overexpression of 
Skp2 in prostate of mice decreased p27kip1 levels, promoting proliferation, 
resulting in hyperplasia and high grade PIN (Shim, 2003). This phenotype is 
more severe than that of p27-deficient mice (Gary, 2004), suggesting that Skp2 
impacts additional targets other than p27kip1 in the prostate.  
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Probasin–prolactin transgenic mice  
The pituitary hormone prolactin (PRL) has been found to have diverse 
effects on the prostate gland. These chiefly include actions related to proliferative 
activity, secretory function and regulation of specific metabolic functions (Costello, 
1994; Reiter, 1999). Transgenic mice which express prostate-specific rat 
prolactin (rPRL) were generated to explore the role of locally produced PRL, 
possibly acting via an auto- or paracrine mechanism, in promoting abnormal 
prostate growth. The Pb-rPRL transgenic males developed a significant 
enlargement of the prostate gland, characterized primarily by hyperplasia of the 
stromal compartment, distended ductal structures, and focal areas of glandular 
dysplasia (Kindblom, 2003). 
 
Estrogen receptor mutant mice 
Estrogens have important roles in differentiation and maintenance of 
reproductive tissues, and also influence lipid metabolism and bone remodeling. 
There are two estrogen receptor (ERs) identified thus far, ERα and β. The adult 
male ERα knockout (KO) mouse prostate shows normal development and 
histology. The weight of seminal vesicle and ventral prostate of ERα KO is 
increased with aging (Couse, 1997), but remains histologically indistinguishable 
from that of wild-type littermates (Prins, 2001). Mice lacking ERβ were generated 
by inserting a neomycin resistance gene into exon 3 of the coding region by 
using homologous recombination in embryonic stem cells. Young, sexually 
mature male mice demonstrated no overt abnormalities and reproduce normally. 
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However, older mutant males presented with prostate and bladder hyperplasia 
(Krege, 1998). Furthermore, in prostates of ERβ-null mice, AR levels are 
increased and the tissue contains multiple hyperplastic foci (Weihua, 2001).  
 
FLiMP mice 
 Human 15-lipoxygenase-1 (15-LO-1) metabolizes polyunsaturated fatty 
acids and has a physiological role in remodeling membrane. This enzyme is also 
known to function in atherosclerosis, inflammation and and carcinogenesis. The 
conditional overexpression of human 15-LO-1 using Cre-LoxP method (PbCre 
and  CAG–loxP–CAT–loxP–h15-LO-1) led to epithelial hyperplasia and PIN 
lesions (Kelavkar, 2006). This model implies possible dietary prevention of 
prostate cancer. 
 
Conditional p53 knockout model  
 p53 is a well-studied tumor suppressor gene and mutation in p53 is 
associated with metastasis and hormone refractory prostate cancers (Bookstein, 
1993; Heidenberg, 1995). To see the effects of altered p53 pathway on prostate 
cancer development, conditional p53 deletion model was generated (Zhou, 2006). 
Despite critical role of p53 in general human carcinogenesis, these mice 
displayed only PIN lesions without progression to invasive carcinoma. In addition, 
Chen et al. independently showed that p53 inactivation alone did not display 
histological abnormalities (Chen, 2005). 
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Models that develop invasive cancer without metastasis 
Several models have been generated that develop invasive prostate 
carcinoma which, however, do not lead to the efficient progression to metastasis 
over the lifetime of the organism. Most of these models are obtained by enforced 
expression of potent oncogenes or multiple mutations in tumor suppressor genes. 
 
Probasin–myc transgenic mice 
As mentioned above, high-level expression of c-MYC in the mouse 
prostate resulted in the development of PIN followed by invasive 
adenocarcinoma, while expression of low levels results only in PIN (Ellwood-Yen, 
2003; Zhang, 2000b). This dosage dependence of the cancer phenotype may be 
a reflection of the fact that expression of c-Myc at different levels activates 
distinct gene programs (Guo, 2000).  
 
Nkx3.1-/- & Pten+/- compound mutant mice 
Loss of function in Nkx3.1 and Pten cooperate in prostate carcinogenesis 
in mice. Nkx3.1-/- and Pten+/- compound mutant mice display an increased 
incidence of high grade PIN (HGPIN)/early carcinoma lesions, resembling early 
stages of human prostate carcinogenesis (Kim, 2002).  
 
LPb-Tag (LADY) transgenic mice 
Several transgenic lines expressing SV40 large T-antigen under the 
control of the long Probasin promoter have been generated (Kasper, 1998; 
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Masumori, 2001). Some of these lines develop invasive carcinoma while only 
one line (12T-10) line developed metastatic disease (Masumori, 2001). 
Metastatic potential can be conferred on non-metastatic LADY tumors by 
expression of a Probasin-Hepsin transgene (Klezovitch, 2004). Hepsin is a cell 
surface serine protease that is markedly upregulated in human prostate cancer.  
 
Ptenhy/- mice 
 A hypomorphic Pten mouse mutant series with decreasing Pten levels and 
activity were generated by homologous recombination: Pten+/+ > Ptenhy/+ > Pten+/- 
> Ptenhy/- > Pten prostate-specific conditional KO mutants (two types; inactivated 
focally or throughout the entire prostatic epithelium). Among these mice, Ptenhy/- 
mutants displayed massive prostate hyperplasia and invasive prostate cancer. 
Pten+/- mutants, however, developed moderate/low grade PIN (LGPIN) at 
incomplete penetrance but never developed invasive cancer (Trotman, 2003). 
This important study demonstrates the critical dependence of prostate 
tumorigenesis on tumor suppressor gene (TSG) dosage. 
 
Conditional p53 and Pten knockout mice 
 As described above, p53 deficiency alone did not show any abnormality in 
mouse prostate but it dramatically cooperated with conditional Pten deletion 
(Chen, 2005). Dual conditional inactivation of p53 and Pten caused prostate 
cancer without distant metastasis (until 2.5 years) but all these mice died by 7 
months. 
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Conditional APC-null mice 
 β-catenin is a multi-functional molecule regulating cell growth and it plays 
an important role in Wnt signaling pathway together with Adenomatous polyposis 
coli (Apc). When Apc was deleted in mouse prostate by the action of PbCre to 
alter Wnt signaling pathway, invasive adenocarcinoma without metastasis was 
developed (Bruxvoort, 2007). 
 
Models that develop metastatic prostate cancer 
Most of the models that efficiently develop metastatic prostate cancer are 
based on the expression of the SV40 large T- and small t (T/t)-antigens. The 
PbCre and Ptenloxp/loxp conditional model is unique as a model in which deletion 
of a single TSG efficiently leads to the development of metastatic disease. 
 
TRAMP mice  
TRAMP mice express the T/t antigens under the control of short Probasin 
promoter and develop metastatic cancer (Gingrich, 1999; Greenberg, 1995). It 
has been demonstrated that the TRAMP mice develop adenocarcinoma that will 
sometimes display neuroendocrine-like features in very late stages of disease 
(Kaplan-Lefko, 2003). Further genetic manipulation of TRAMP mice has provided 
additional valuable insights into the mechanisms of prostate tumor initiation and 
progression in vivo. For example, TRAMP mice lacking the transcription factor 
early growth response gene (Egr) 1 were generated to test the role of Egr1 in 
prostate tumorigenesis (Abdulkadir, 2001). Egr1 is known to be overexpressed in 
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human prostate tumors (Abdulkadir, 2001; Eid, 1998). TRAMP;Egr1–/– mice show 
a significant delay in progression from PIN to invasive carcinoma (Abdulkadir, 
2001).  
 
Other T/t antigen models 
Other T/t antigen models, all of which develop metastatic prostate cancer 
include C3(1)-Tag in which the regulatory control of the rat prostatic steroid-
binding protein C3(1) gene was used (Shibata, 1996): PSP94-Tag mice (Gabril, 
2002), PSP-KIMAP mice (Duan, 2005), gp91-phox-Tag mice (Skalnik, 1991) and 
cryptdin2-Tag mice (Garabedian, 1998). In cryptdin2-Tag mice, the transgene is 
expressed in the neuroendocrine cells of the prostate, thus the tumors that 
develop in these animals are composed of neuroendocrine cells. 
 
LADY model line 12T-10  
Model line 12T-10 of LPb-Tag transgenic mice develops precursor lesions 
more analogous to human high grade PIN (HGPIN), without associated 
prominent stromal hypercellularity (also more similar to human prostate cancer). 
Furthermore, this line predictably develops invasive carcinoma with glandular 
differentiation (adenocarcinoma) as well as neuroendocrine prostate cancer that 
commonly metastasizes (Masumori, 2001).  
 
 46
Conditional Pten knockout model 
 Pten/mutated in multiple advanced cancers (MMAC) 1 is a phosphatase 
and a tumor suppressor gene implicated in a wide range of human cancers. 
Homozygous deletion and point mutations were observed in human prostate 
cancer samples and cell lines (Li, 1997; Steck, 1997) (CHAPTER I). Pten 
inactivation resulted in early embryonic lethality (Di Cristofano, 1998). To achieve 
prostate-specific deletion of Pten, PbCre;Ptenloxp/loxp (Wang, 2003), 
MMTVCre;Ptenloxp/loxp (Backman, 2004), PSA-Cre;Ptenloxp/loxp (Ma, 2005), and 
PSA-Cre-ERT2;Ptenloxp/lox (Ratnacaram, 2008) have been generated although 
floxed exons of Pten gene are different each other. In all models Pten loss leads 
to a significant shortened latency of PIN formation and results in prostate cancer 
progression but metastasis has thus far been observed only in PbCre and 
Ptenloxp/loxp mice (Wang, 2003) and PSA-Cre;Ptenloxp/loxp (Ma, 2005). PSA-Cre-
ERT2;Ptenloxp/lox model provides spatiotemporal control of somatic mutagenesis 
using Cre-ERT2 which is active upon tamoxifen treatment (Ratnacaram, 2008). 
 
Probasin-AR (E231G) transgenic mice 
Although overexpression of wild-type AR does not lead to prostate cancer, 
overexpression of AR-E231G, a mutant AR, leads to metastatic prostate cancer 
in 100% of mice examined (Han, 2005). These results established AR as an 
oncogene in prostate cancer. Furthermore, since expression of AR-T857A, a 
different mutant AR, does not lead to cancer phenotype, the E231G mutation is 
proved to be a specific oncogenic gain of function. 
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Conditional p53 and Rb double knockout mice  
Although inactivation of either p53 or Rb led to PIN without the phenotype 
of carcinoma, two mutations synergistically cooperated and induced metastatic 
carcinoma (Zhou, 2006). These tumors showed neuroendocrine differentiation 
and were resistant to androgen ablation. They shared genetic expression 
signatures commonly found in human prostate cancers. 
 
Conditional Pten-heterozygous & Fgf8b-overexpressing mice 
 By crossing ARR2Pb-Fgf8b (fibroblast growth factor 8 isoform b) and 
conditional Pten deletion mice (PbCre;Ptenloxp/loxp), mice with Fgf8b 
overexpression and conditional Pten heterozygosity were generated (Zhong, 
2006). As reported previously (Song, 2002), Mice either with Fgf8b 
overexpression or with Pten heterozygosity alone displayed PIN lesions, but their 
cooperation dramatically accelerated the disease progression by developing 
adenocarcinoma and metastatsis. 
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Therapeutic Applications of GEM Models of Prostate Cancer 
 
Immunologically intact mice with defined genetic lesions have obvious 
advantages in the development of new therapeutic agents. Some of the 
genetically engineered murine (GEM) models described above have been used 
for testing new therapeutic and agents, a few of which will be described.  
 
MPAKT model  
In this model, constitutive Akt expression led to p70S6K activation and the 
development of PIN, a phenotype that bears many of the hallmarks of 
mammalian target of rapamycin (mTOR) activation. This suggests that activation 
of mTOR downstream of Akt may be linked to the development of PIN in these 
mice. To test this, MPAKT mice were treated with the mTOR inhibitor RAD001. 
The results of this experiment indicated that the expansion of the intraluminal 
cells driven by Akt expression is mTOR-dependent. mTOR inhibition induces the 
complete reversal of the neoplastic phenotype in the prostate of these transgenic 
mice through apoptosis of epithelial cells (Majumder, 2004).  
 
TRAMP mice  
TRAMP mice have been widely used in testing therapeutic and 
chemopreventive agents. 
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Immunotherapy 
In one study, adoptive transfer of tumor-specific memory lymphocytes 
against Tag prevented tumor development and progression. This adoptive 
transfer did not influence on the morphology and function of tissues involved 
(Granziero, 1999). Anti-cytotoxic T-lymphocyte antigen (CTLA)-4, an inhibitory 
receptor on T cells, plays a critical role in attenuating T-cell responses (Linsley, 
1991). Anti-CTLA-4 antibodies that block interactions between CTLA-4 and B7 
(CD80 or CD86) (Lenschow, 1996), enhance in vivo T-cell responses to peptides, 
superantigens, and parasites (Thompson, 1997). CTLA-4 blockade in 
combination with irradiated tumor cell vaccines was effective at reducing tumor 
incidence and the severity of prostatic lesions in TRAMP mice (Hurwitz, 2000).  
 
Chemoprevention 
Nonsteroidal anti-inflammatory drugs such as celecoxib (Celebrex®) and 
E-7869 (R-flurbiprofen), have been demonstrated to significantly reduce tumor 
progression in TRAMP mice, possibly due to effects on cyclooxygenase (COX)-2 
enzyme activity or mRNA levels (Gupta, 2004; Wechter, 2000). When OSU03012, 
a celecoxib-derived PDK1 inhibitor was used to treat TRAMP mice, PIN lesions 
were reduced but it did not affect the incidence of carcinoma or metastasis 
(Sargeant, 2007). Other agents demonstrated to function as chemopreventive 
agents in TRAMP mice include α-difluoromethylornithine (α-DFMO) which is an 
irreversible inhibitor of the enzyme ornithine decarboxylase (ODC) (Gupta, 2000), 
green tea polyphenols (Gupta, 2001), soy constituent genistein (Mentor-Marcel, 
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2001; Wang, 2007), tamoxifen derivative toremifene (Raghow, 2002), all-trans 
retinoic acid (ATRA) (Huss, 2004), grape seed extract (GSE) (Raina, 2007), 
natural polyphenolic phytochemical resveratrol (Harper, 2007), and herbal extract 
Nexrutine® (Kumar, 2007). The LADY transgenic model has also been used to 
demonstrate that dietary antioxidants (vitamin E, selenium, and lycopene) at a 
human achievable dose significantly inhibit prostate cancer development and 
increase the degree of survival of these mice (Venkateswaran, 2004).  
 
Gene therapy 
The TRAMP mice were treated with intra-prostatic injection containing 
OAdV220, an ovine adenovirus which expresses PNP gene under the control of 
the Rous sarcoma virus promoter, followed by systemic fludarabine treatment. 
Purine nucleoside phosphorylase (PNP) is an Escherichia coli enzyme that 
converts the prodrug fludarabine phosphate into the highly toxic metabolite 2-
fluoroadenine (2-FA) can inhibit nucleic acids and protein synthesis (Martiniello-
Wilks, 2002; Secrist, 1999; Voeks, 2002). The weight change of the genitourinary 
tract, seminal vesicles, prostate and animal survival was determined. The results 
indicate that PNP-gene-directed enzyme prodrug therapy delivered by ovine 
adenovirus vector caused significant suppression of prostate cancer progression 
and increased survival (Martiniello-Wilks, 2004). In addition, when TRAMP mice 
were treated with mouse endostatin and angiostatin using recombinant adeno-
associated virus-6 (rAAV-6) by intramuscular injection at early stages, this 
therapy remarkably prolonged survival rate (Isayeva, 2007). 
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Conclusions 
 
The transgenic mice described herein have greatly enhanced our 
knowledge of the mechanisms of prostate carcinogenesis. Among the genes with 
known roles in human prostate tumorigenesis, analysis of genetically engineered 
mice has revealed prominent roles for the tumor suppressor Pten and the 
oncogene c-Myc in prostate tumorigenesis. In particular, conditional deletion of 
Pten in the prostate using PbCre mice efficiently induces prostate carcinoma 
which metastasizes to distant organs. This and other models may now be used 
for further dissection of mechanisms of tumorigenesis and for testing new 
targeted therapies and chemopreventive agents. 
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Future Perspective 
 
Although currently available models provide valuable tools for studying 
prostate carcinogenesis, several improvements can be made to generate more 
refined models with better utility. In general, it will be important to generate 
models based on genes and pathways with relevance to human prostate 
carcinogenesis. This will become easier as more human prostate cancer genes 
are discovered and their pathways defined. The manner in which the relevant 
genes are disrupted is also important. Like conditional Pten deletion model 
executed by tamoxifen-dependent Cre (Cre-ER) (Ratnacaram, 2008), temporal 
and spatial gene inactivation or overexpression in the adult prostate, will mimic 
the situation in human prostate cancer more closely. Strategies that allow 
regulated gene expression may provide the additional flexibility of studying the 
effects of mutation reversion on cancer survival. The field will clearly benefit also 
from the availability of models that spontaneously develop frequent osteoblastic 
osseous metastases similar to the situation in human prostate cancer. Another 
important issue is the need to develop prostate specific, yet androgen-
independent promoters for transgene expression like PbCre;Z-MYC mice (Kim, 
2009) which will be described in CHAPTER VI. This allows the effects of 
castration on specific oncogene-induced tumors to be investigated and separate 
androgen ablation from the effects of oncogene withdrawal due to transgene 
silencing in models generated with androgen-sensitive promoters like Probasin. 
Moreover, strategies for imaging should be incorporated when making new 
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models to allow easier tracking of the fate of transformed cells in vivo. Figure 9 
outlines some strategies for generation of more refined murine models with 
controlled deletion or activation of cancer-related genes and/or markers to aid 
with in vivo imaging. Consideration of the influence of the tumor 
microenvironment is also essential. Future models should incorporate effects of 
alteration in the stroma as well as inflammation, free radicals, infection or aging. 
The study investigated by Bhowmick and colleagues who demonstrated that 
selective deletion of the prostatic stromal Tgfbr2 promoted the development of 
PIN is a good example (Bhowmick, 2004). Finally, there is a need to use the 
several models of preinvasive neoplasia already generated for chemoprevention 
trials. This will require a standardized pathologic (Shappell, 2004) and/or a 
computer-aided grading system to ensure accuracy and reproducibility (Gary, 
2004). 
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Figure 9. Cre-inducible conditional gene activation/deletion. Conditional 
systems such as the Cre/loxP system can be used to achieve prostate-specific 
deletion of tumor suppressor genes (TSGs) (A) or activation of oncogenes (B) 
and marker genes (C) to aid with mutant cell detection. The conditional activation 
of oncogenes as shown in “B” can provide models in which castration will not 
lead to transgene silencing if the ubiquitous promoter used (ubiquitous promoter) 
is not androgen dependent. Cre: Cre recombinase; STOP: Transcription 
termination signal; TSG: Tumor suppressor gene. 
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CHAPTER III 
 
GENETIC MOSAICISM 
 
Introduction 
 
Genetic mosaicism describes that two cell populations with different 
genetic backgrounds present in one individual originated from one fertilized egg. 
In the area of biology, investigators who seek to characterize in vivo roles or 
functions of genes of interest in normal development or human diseases have 
been utilizing transgenic animals or plants by introducing foreign genes into 
model organisms. Especially to examine human diseases including cancers, 
modeling diseases using laboratory model animals is one of the crucial means to 
study their initiation, progression, and development and test therapeutics 
including drug efficacy. According to a muti-step model of carcinogenesis 
(Fearon, 1990), human somatic cancers are believed to initiate from a single 
mutation in one cell or a few cells in the tissue. The mutant cells either encounter 
a biological barrier, e.g. apoptosis or senescence, or expand clonally. With or 
without additional mutations depending on the importance of the roles of the 
mutated gene during the pathogenesis, the pre-cancerous cells become 
tumorigenic. Therefore, due to the random nature of genetic mutations during 
multi-step cancer development, many human cancers are thought to display 
heterogeneity, so genetic mosaicism is supposed to be an essential part of 
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human somatic carcinogenesis. In addition, during tumorigenesis, the 
interactions between cells with distinct mutations, i.e. between mutant cells and 
surrounding wild type cells or between differentially mutated cells, are believed to 
be important for the disease development. In this sense, it is critical to model 
genetic mosaicism in the same animal or in the same organ or tissue of a single 
animal. Current advances in developing laboratory animal models and methods 
for cancer research demonstrate enormous efforts to elucidate a tumorigenic 
mechanism by mutations in genes of interest and mimic spontaneous somatic 
genetic alterations during human carcinogenesis. This part of the chapter will 
discuss reports where genetic mosaicism or sporadic transgene expression/gene 
deletion in model organisms was induced either intentionally or unexpectedly. In 
addition, advantages and disadvantages of these models will be also addressed. 
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Transgene Silencing and Stochastic Pattern of Gene Expression 
 
 The expression of introduced foreign genes into living organisms is 
frequently silenced (Clark, 1994). This sometimes happens when too few copies 
of the transgene are integrated into the genome, which results in low expression 
or mosaic pattern of gene expression (Stam, 1997). Therefore, the copy number 
of integrated transgene and the integration sites are believed to be critical 
determinants for expression levels (Clark, 1994; Dorer, 1997; Garrick, 1998). 
These factors can cause complete shutdown or a mosaic pattern of transgene 
expression (Martin, 1996). Accordingly, understanding gene silencing 
mechanisms of introduced foreign genes is important to control stochastic 
transgene expression (Figure 10). 
 Integration sites of transgenes are crucial to their eventual expression. 
When transgenes are integrated into certain chromosome loci such as 
euchromatin with high accessibility of transcription factors, there is more chance 
of higher transgene expression and a uniform expression pattern even though 
low numbers of transgene copies are integrated into the genome. However, 
transgenes integrated close to heterochromatin or repetitive DNA sequences 
may show focal expression pattern/gene silencing or less chance of high 
expression. This has been evident in animal models showing position-effect 
variegation (PEV), which is also known to cause mosaic pattern gene expression 
by the relocation of the specific gene into heterochromatin. PEV was first shown 
in Drosophila eye color determination (Muller, 1930) where red-white mosaic eye 
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color is caused by inactivation of the white gene by mutation whose expression 
then results in red eye color. In mammals, BLG/7 transgenic line shows a mosaic 
pattern of beta-lactoglobulin (BLG) transgene expression. In BLG/7 transgenic 
line, a tandem array of ~25 copies of BLG transgene is thought to be integrated 
around the centromere of chromosome 15, which causes variegated pattern of 
BLG expression (Dobie, 1997; Dobie, 1996). 
 The number of inserted transgenes also decides expression levels. In 
plants, T-DNA transfer system tends to insert two or more T-DNAs at the same 
chromosomal region. When T-DNAs are integrated as an inverted repeat (head-
to-head or tail-to-tail fashion), their expression is often low, indicating possible 
transgene silencing (Jones, 1987; Jorgensen, 1987). In addition, when high 
copies of transgene are integrated into the genome of transgenic animals or 
plants, this is sometimes known to cause dominant-negative or other toxic effects 
(Thellmann, 2003). 
 Strain-specific modifier genes in mice have also been reported to regulate 
transgenic loci (Allen, 1990; Engler, 1991; Hadchouel, 1987; McGowan, 1989). 
Mouse strains such as Balb/c, C57BL/6 and DDK showed very low expression of 
a transgene while high levels of transgene expression were observed in DBA/2 
and CFLP backgrounds.  
 In addition, post-transcriptional gene silencing can block transgene 
expression by an unknown mechanism, which occurs when mRNA is not 
accumulated, although the gene promoter is active (Matzke, 2004; Stam, 1997). 
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This phenomenon is evident in virus-resistant plants when viral transgene is 
introduced (Smith, 1994). 
 DNA composition or structure of the transgene can help determine 
silencing. Transgene methylation (Kothary, 1992; Matzke, 1998) or DNase I 
hypersensitivity (Pourcel, 1990) was shown to promote gene silencing, 
suggesting that certain nucleotide compositions in the transgene may attract 
silencing methylation or be susceptible to degradation. Also, the structure of the 
transgene DNA is a possible cause of gene silencing. In Xenopus transgenesis, 
circular DNA is more prone to be silenced than linear DNA because the former is 
unable to form concatemers or undergo DNA replication, so is less likely to be 
integrated into genome (Marini, 1988).  
 In addition, transgene expression is also affected by stress effects, such 
as heat shock or cold shock (Kothary, 1992). 
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Figure 10. Factors that affect transgene expression. Multiple mechanisms are 
known to control transgene expression and these cause uniform, stochastic 
expression or even complete shutdown of transgene expression. 
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Methods without LoxP-Cre System for Stochastic Transgene Expression 
 
 With the understanding of transgene silencing mechanism, many efforts to 
generate transgenic animals with mosaic pattern of transgene expression 
following direct integration of transgenes have been successful despite some of 
the advantages and disadvantages. Enhanced green fluorescent protein (eGFP)-
expressing embryos generated by a somatic cell nuclear transfer (NT) from an 
ear skin fibroblast cell line of a newborn pig electroporated with eGFP gene 
displayed a mosaic pattern of eGFP expression in contrast to uniform expression 
of eGFP in embryos generated by NT from fetal fibroblasts (Park, 2002). This 
was probably due to different integration sites of eGFP transgene in newborn cell 
nuclei or fetal cell nuclei. It is also possible that animal cells at different 
developmental stages may show different susceptibility to transgene integration 
or different levels of transgene expression, but more tests are needed to prove 
these possibilities. 
 Two mouse embryonic stem cell populations that overexpress either 
enhanced yellow fluorescent protein (eYFP) or enhanced cyan fluorescent 
protein (eCFP) were mixed and transplanted to get chimeric mice. The resultant 
chimeric mice exhibited eYFP-positive cells and eCFP-positive cells in the same 
organs within a single individual mouse, demonstrating possible method to 
control the ratio of genetic mosaicism (Hadjantonakis, 2002). 
 Restriction enzyme mediated integration (REMI) of DNA is often used for 
Xenopus transgenesis (Kroll, 1996). The sperm nuclei whose head membranes 
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are disrupted are incubated with linear transgene DNA for short periods of time 
(1-2min) followed by injection of the sperms into unfertilized eggs. This increased 
mosaic expression pattern of transgene in muscle, compared to longer periods of 
incubation (10-15min) (Sparrow, 2000), all of which demonstrates that mosaicism 
could be controlled at the stage of transgene integration by varying incubation 
time. In addition, direct injection of transgene DNA into fertilized eggs is also 
known to result in mosaicism (Christian, 1993).  
 All methods described above, however, utilize multi-copy integration of 
transgenes into the genome of target animals. This is sometimes problematic 
because multi-copy transgenes cause random insertional mutagenesis as well as 
deleterious effects on the model animals (Thellmann, 2003). Therefore, it is 
probably necessary to introduce a single copy transgene into the chosen 
chromosomal loci. Targeting single copy gene integration into chosen location in 
the genome also has subsequently been developed (Bronson, 1996; Misra, 
2002). In this case, chromosomal sites where the foreign gene expression is 
favorable are selected, and however, the key is selection of integration sites 
where “moderate” expression of transgene can result in focal pattern expression 
instead of uniform expression. 
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Methods with LoxP-Cre System for Stochastic Transgene Expression 
 
 Since the 1980s, site-specific recombination using loxP-Cre system has 
allowed target genes to be deleted or expressed at the tissues of interest. 
Recently, several efforts using this method to introduce mosaic transgene 
expression or target gene deletion have been made and demonstrate promising 
control of stochastic gene expression or deletion in a tissue-specific manner 
(Figure 11). In this section, mosaic genetic alteration methods mediated by loxP-
Cre recombination will be discussed.  
  
Control of mosaicism by virus-mediated gene delivery 
 Virus-mediated gene delivery into target organs is reported to be ideal for 
mosaic transgene expression pattern (Figure 11A) (Chen, 2000; Tamamaki, 
2000). To generate genetic mosaicism by activating oncogenes in a limited 
number of cells in the tissue of interest, Marumoto et al. injected lentiviral vectors 
that had H-Ras gene or activated AKT gene with loxP sites into Cre mice that 
express Cre recombinase in CFAP+ (glial fibrillary acidic protein-positive) cells in 
the adult brain to transduce stem/progenitor cells or terminally differentiated cells 
(Marumoto, 2009). Viral infection of either H-Ras or AKT did not develop a brain 
tumor in all the areas infected, as reported previously (Holland, 2000). However, 
when lentiviral vectors of H-Ras and AKT were injected together to examine 
cooperation of two oncogenic mutations, 50-60 cells were infected successfully 
demonstrating focal transgene expression - most (>98%) showed expression of 
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H-Ras and AKT. Also, these cooperative mutations resulted in tumors in some 
areas of infection after 4-5 months, and most of the cells in the tumor mass were 
positive for both oncogene expressions, suggesting expansion of highly 
proliferative double mutant cells (Marumoto, 2009). 
 
Control of mosaicism by modulating loxP sites 
 Numerous transgenic mouse lines that express multiple fluorescent 
proteins in a mosaic pattern have been generated in neurobiology using the loxP-
Cre system. Labeling neurons with XFPs, e.g. eGFP, eCFP, eRFP or eYFP, 
helps to examine neuronal structure dynamics and functions during brain 
development (Chakravarthy, 2008; Livet, 2007; Zong, 2005). Basically, two ways 
have been developed to affect stochastic transgene expression by modulating 
loxP sites (Figure 11B). First, when there are mutations in the spacer region of 
loxP sites, recombination efficiency became varied in vitro (Lee, 1998), although 
the efficiency was not changed in vivo (Livet, 2007). Second, it has been shown 
in an in vivo study that the longer the distance between two loxP sites is, the less 
the recombination efficiency (Zheng, 2000). Moreover, a new in vitro method to 
regulate sparseness of transgene expression has been developed based on the 
correlation between the loxP-loxP distance and recombination efficiency (Wang, 
2009). 
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Control of mosaicism by modulating Cre recombinase activation 
 Recently, improved methods to generate transgenic mice with genetic 
mosaicism have developed using loxP-Cre system. Akyol et al. developed a 
method to activate Cre recombinase (G22Cre) sporadically in the caudal region 
of embryo, and the cecum and colon of adult mice. The mosaicism was shown by 
the pattern of β-galactosidase expression in G22Cre;Rosa26 bigenic mice (Akyol, 
2008; Soriano, 1999). The human CDX2P9.5 gene promoter of this novel Cre 
construct is known to be active in caudal region of the developing mouse embryo, 
and in the distal small intestine, cecum and colon during late gestation and adult 
tissues (Hinoi, 2007). An array of 22 guanine nucleotides (22G) was added 
downstream of ATG initiation codon of Cre recombinase. Interestingly, Cre 
expression was active only if there was a frameshift reversion mutation (or 
microsatellite instability/MSI), i.e. conversion of 22G to 21G by frameshift 
mutation, which results in active Cre expression from the mutated construct 
(Figure 11C). 
 Despite the promising nature of focal transgene expression, this model 
has several potential problems. According to Southern blot analysis, about ~80 
copies of the transgene are integrated into the mouse genome, so it may cause 
unexpected insertional mutagenesis. Until an appropriate frameshift mutation 
occurs, unknown proteins that are generated from unmutated Cre constructs may 
affect cellular functions. In addition, although Cre activation can be transmitted 
through three generations, stable germline transmission of the same pattern of 
Cre activity was not verified due to the random nature of mutation that occurred 
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in the Cre constructs. Different copy numbers of integrated trasgene may be 
necessary to get a similar frameshift mutation rate in tissues other than brain 
cells. 
 Similarly, Miller et al. devised a novel transgenic mice that overexpressed 
Cre recombinase sporadically (Miller, 2008). Pms2 gene is a human homologue 
of yeast postmeiotic segregation increased 2 (Pms2) gene and is involved in 
DNA mismatch repair. Homozygous inactivation of Pms2 is reported to develop 
lymphoma (94%) and some sarcomas, but not intestinal adenoma or 
adenocarcinoma (Prolla, 1998). By replacing exon 2 of Pms2 gene with 
frameshifted Cre recombinase construct including a sequence of 12 adenine 
nucleotides (12ACre), either homozygous Pms2cre/cre or heterozygous Pms2cre/+ 
is generated (Figure 11D). Since Pms2cre/cre results in complete loss of Pms2 
function, a frameshift mutation in the sequence of adenine nucleotides occurs 
frequently and the resultant 11ACre activates Cre expression in the intestine, 
pancreas, kidney, liver and muscle in a mosaic manner, which is consistent with 
Pms2 gene expression patterns (Narayanan, 1997). In contrast, Pms2 is partially 
functional in Pms2cre/+, and the heterozygous Pms2cre/+ mice displayed much less 
Cre activity producing a rare β-galactosidase expression in Pms2cre/+;Rosa26 
bigenic mice. 
 However, this model also has several possible problems like the Akyol et 
al. model. First, a majority of Pms2 knockout mice developed lymphoma, so the 
Cre line can not be used for lymphoma-related studies. Also, 50% of Pms2cre/cre 
mice died from lymphoma at 10 months, so this line is only useful for early-
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developing cancer models, whose tumorigenesis study can be completed within 
10 months. In addition, a defect in DNA mismatch repair may cause potential 
innate tumorigenesis, and this may make data interpretation difficult. 
 
Control of mosaicism using inducible gene expression systems 
 In addition to conventional loxP-Cre methods, inducible temporal and 
spatial control of gene expression has been developed. They are ligand-inducible 
Cre recombinases such as Cre-ER (Tamoxifne-inducible) (Figure 11E) (Feil, 
1996), Cre-hPR891HBD (RU 486-inducible) (Kellendonk, 1996), or tetracycline-
controllable tTA/rtTA (Jaisser, 2000). In these systems, the amount or dose of 
ligand (e.g. Tamoxifen) given to bigenic mice (e.g. Cre-ER;Z/EG) to induce 
transgene (eGFP) expression was shown to alter the degree of mosicism (Shi, 
2007). 
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Figure 11. Methods using loxP-Cre to introduce mosaic gene alterations in 
model organisms. LoxP-Cre system has been widely used to induce stochastic 
gene alterations by virus-mediated gene delivery (A), modulating loxP sites (B) or 
Cre recombinase activation via frameshift mutation (C and D), and changing 
dose of ligands to activate Cre (E). 
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CHAPTER IV 
 
GENERATION OF TRANSGENIC MICE WITH FOCAL ONCOGENE C-MYC 
ACTIVATION IN MULTIPLE TISSUES 
 
 
[This part is adapted from {Roh, M., Kim, J., Song, C., Wills, M., Abdulkadir, S.A., 
Genesis (2006)}] 
 
Introduction 
 
 As discussed in CHAPTER II, the analysis of the pathological role of 
oncogene expression will be greatly aided by the availability of suitable animal 
models in which specific oncogenes can be activated, in particular cell types and 
at particular stages of development. The c-MYC oncogenes have been 
implicated in tumorigenesis, including in lymphomas and prostate cancers. In 
human prostate cancer, for example, c-MYC gene amplification was reported in 
up to 30 % of samples (Jenkins, 1997; Nesbit, 1999; Qian, 1997; Sato, 1999) and 
its overexpression is thought to be an early event based on 
immunohistochemical analysis (Gurel, 2008) (CHAPTER I). In transgenic mice, 
targeted overexpression of c-Myc has been shown to be sufficient to induce 
cancer in various tissues (Jensen, 2003; Moroy, 1991; Nesbit, 1999; Pelengaris, 
2002a; Pelengaris, 2002b; Pelengaris, 1999; Zhang, 2000b). The effects of c-
Myc on proliferation or apoptosis differ depending on other cellular factors, for 
example, survival and apoptotic factors (Pelengaris, 2002a; Pelengaris, 2002b; 
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Pelengaris, 1999). In the prostate, targeted c-Myc expression using prostate-
specific promoters such as C3, Probasin (Pb), and modified Probasin promoter 
called ARR2Pb in the prostate has been shown to induce a neoplastic phenotype 
(Ellwood-Yen, 2003; Zhang, 2000a). One limitation of these mouse models, 
however, relates to the response to androgen ablation because all these 
promoters are themselves regulated by androgen, as discussed in CHAPTER II. 
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Results 
 
Construction of Z-MYC plasmid and in vitro validation of Cre recombination 
We generated transgenic mouse lines for Cre-inducible c-MYC expression, 
called Z-MYC. The transgenic construct consists of CMV enhancer/β-actin 
promoter followed by a loxP-flanked cassette of the β-galactosidase/Neomycin 
resistance fusion gene (β-geo) and a triple polyA transcription termination signal 
(STOP) (Zinyk, 1998). Downstream of this cassette is human c-MYC (Figure 12). 
The presence of a “STOP” signal blocks expression of the downstream gene (c-
MYC) until Cre-mediated recombination. The CMV enhancer/ β-actin promoter 
has been shown to drive high levels of expression of downstream target genes in 
various cell types and tissues (Garg, 2004; Lobe, 1999; Niwa, 1991; Sawicki, 
1998). The ability of the transgenic construct to serve as a Cre substrate was first 
evaluated in vitro. The Z-MYC construct was transfected into RWPE-1, benign 
human prostate epithelial cells, alone or in combination with a Cre expression 
plasmid (EF1alpha-Cre) (Le, 1999). Expression of Cre resulted in induction of 
expression of the transgenic c-MYC protein (Figure 12).  
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Figure 12. Schematic diagram of construct used in generating Z-MYC 
transgenic mice and in vitro validation of construct integrity. (A) describes 
schematic diagram of Z-MYC construct. CMV enhancer/β-actin promoter, β-
galactosidase/Neomycin resistance fusion gene (β-geo), stop signal, human c-
MYC, and poly-A site are depicted as boxes. (B) demonstrates in vitro validation 
of construct integrity. RWPE-1 stable cell line having Z-MYC plasmid was 
transfected with EF1 alpha-Cre (Cre), and samples were processed for c-MYC 
immunoblotting. The cells with both transgenes, Z-MYC and Cre, showed strong 
induction of c-MYC (lane 1), whereas single gene transfected cells did not (lane 
2). 
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Introduction of Z-MYC construct into mouse ES cells and ES cell screening 
Next, the Z-MYC construct was transfected into embryonic stem (ES) cells 
and the cells were subjected to G418 selection. These were then stained for lacZ 
(Figure 13) to identify clones displaying strong and uniform lacZ expression. This 
lacZ positive selection step is thought to improve the likelihood of generating 
mice with widespread transgene expression when subsequently generated from 
the ES clones (Lobe, 1999). For most of the clones, southern blot analysis was 
performed to determine the transgene copy number (Figure 13), with the goal of 
selecting clones with a single copy transgene for the generation of mice, to avoid 
possible complications that may arise due to integration of a multiple loxP 
containing transgene. Selected clones with a single copy transgene were further 
expanded, and infected with adenovirus expressing Cre or GFP control. Cell 
lysates were prepared and Cre-mediated recombination was confirmed by 
western blotting in c-MYC lines (data not shown). Clones displaying strong and 
uniform lacZ expression were chosen for injection into blastocysts to generate 
transgenic mice. 
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Figure 13. LacZ screening of Z-MYC-transfected ES cell clones and 
southern blot screening of ES clones for gene copy number. (A) shows lacZ 
screening of ES cell clones. ES cells were transfected with Z-MYC and stained 
for lacZ expression. Some lacZ positive clones are indicated (arrows). Shown in 
(B) is southern blot screening of ES clones. ES cell clones showing strong and 
uniform expression of lacZ from (A) were expanded and DNA samples were 
prepared. Plasmid DNA was used as a copy number control. Probes are P-32-
labeled human c-MYC digested from Z-MYC plasmid. Several ES cell clones 
which have a single copy of transgene were indicated as *. NS: nonspecific 
bands. 
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Mosaic expression pattern of Z-MYC construct 
 The resulting Z-MYC male chimeric mice were bred with C57BL/6 females 
to establish Z-MYC (two lines) mouse lines. Z-MYC line 1 was generated from 
ES cells with a single-copy transgene integration event. To determine the 
expression pattern of transgene in various tissues, we first performed β-
galactosidase staining using 8-25 week old mice. Strong β-galactosidase 
expression was detected in a mosaic pattern in a variety of tissues in Z-MYC line 
1 transgenic mice, including prostatic epithelium, lung vascular and airway 
smooth muscle, retinal photoreceptor layer, kidney tubules, bladder smooth 
muscle, brain neurons, bone marrow, and spleen (Figure 14). Z-MYC line 2 also 
showed mosaic expression pattern of β-galactosidase in prostatic stroma 
(smooth muscle) and in the smooth muscle of various tissues including bladder, 
small intestine, lung (vascular and airway), skin and stomach. Cardiac muscle 
and skeletal muscle also showed positive staining for lacZ in this line (Figure 15). 
The skeletal muscle showed the most uniform expression pattern. Interestingly, 
all our lines showed a mosaic pattern of transgene expression, which may have 
distinct advantages in sporadic activation of oncogene expression in the study of 
tumorigenesis. 
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Figure 14. LacZ expression in Z-MYC transgenic mouse line 1. β-
galactosidase staining of tissues from Z-MYC line 1 (B-I, K-L), or littermate 
control (A, J). LacZ expression in all tissues occurs in a mosaic pattern. (A) 
prostate from Z-MYC negative control mouse. (B) Prostate and skeletal muscle 
(S.M.) from Z-MYC positive mouse. Note mosaic expression in prostate luminal 
epithelial cells. (C) High power image of prostate section in “B”. (D) Lung, 
showing lacZ positive cells in the vascular and airway smooth muscle. (E) 
Transverse section through the eye with lacZ expression in part of the retina. (F) 
High power image of eye section from “E” showing lacZ expression in 
photoreceptor layer of the retina (2). 1: pigment epithelium layer; 2: 
photoreceptor layer; 3: outer nuclear layer; 4: outer plexiform layer. (G) Kidney, 
showing expression in some tubules. (H) Bladder, showing lacZ expression in 
smooth muscle. (I) Cerebral cortex, showing positive cells in some neurons. (J) 
Bone marrow from wild type animal. (K) Bone marrow from Z-MYC line 1. Some 
hematopoietic progenitor cells are positive. (L) Spleen from Z-MYC line 1 
showing some positive cells including megakaryocytes. 10-13 week old animals 
were used. 
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Figure 15. LacZ expression in Z-MYC transgenic mouse line 2. β-
galactosidase staining of tissues from Z-MYC line 2 (E-L), or littermate control (A-
D). LacZ expression in all tissues occurs in a mosaic pattern, with skeletal 
muscle showing the most uniform expression pattern. (A) Prostate. (B) Bladder. 
(C) Small intestine. (D) Lung. (E) Prostate, showing lacZ expression in stroma. 
(F) Bladder, showing expression in smooth muscle. (G) Small intestine, showing 
expression in smooth muscle. (H) Lung, showing expression in vascular and 
airway smooth muscle. (I) Skin, showing expression in muscle. (J) Skeletal 
muscle. (K) Cardiac muscle. (L) Stomach, with expression in muscle layer. 20-25 
week old animals were used. 
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Tissue-specific overexpression of c-Myc after Cre excision 
 To test Cre-mediated induction of transgene expression in vivo, we bred 
Z-MYC positive mice with smooth muscle myosin heavy chain (smMHC)-Cre 
transgenic mice (Regan, 2000; Xin, 2002). The smMHC promoter can drive 
smooth muscle-specific gene expression during development as well as in the 
adult mouse, and has been used for the generation of mice expressing Cre 
recombinase in smooth muscle tissues (Regan, 2000; Xin, 2002). RT-PCR, using 
the smMHC-Cre;Z-MYC double positive mouse, confirmed smooth muscle-
specific expression of human c-MYC transgene (Figure 16A). Western blotting, 
using anti-c-MYC antibody, also confirmed smooth muscle-specific expression of 
c-MYC transgene after Cre recombination (Figure 16B).  
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Figure 16. Evidence of Cre-mediated recombination of the Z-MYC construct 
in vivo. (A) RT-PCR using smMHC-Cre;Z-MYC double positive mouse and Z-
MYC single positive control confirmed smooth muscle-specific expression of c-
MYC transgene. (B) Western blotting showing c-MYC expression in smMHC-
Cre;Z-MYC double positive mouse, but not in Z-MYC single positive mouse. Line 
2 Z-MYC mouse lines were used. NS: nonspecific bands. 8-9 and 4 weeks old 
mice for A and B were used in these experiments, respectively. Error bars = SD 
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Discussion 
 
 In this study, we generated novel transgenic mice with latent c-Myc 
mutation in various tissues. As discussed in Genetic Mosaicism in CHAPTER III, 
copy number of introduced trangene and chromosomal loci where the transgene 
is integrated are the most critical factors to decide expression levels and 
expression pattern of the transgene. Based on the lacZ reporter expression and 
c-MYC mRNA expression after tissue-specific Cre excision, Z-MYC mice 
demonstrated quite strong expression of the transgene, although Z-MYC mice 
have only one copy of Z-MYC transagene (hemizygous). Integration of one copy 
of floxed transgene into the chromosomal locus is crucial because unwanted long 
chromosomal regions could be deleted by Cre if multiple copies are integrated 
into the same chromosome (Figure 17). This may cause fatal mutations and 
make data interpretation very difficult. Also, despite the control of the global actin 
promoter, transgene expression is focally activated instead of uniformly. This is 
probably because Z-MYC transgene is integrated into an intermediate area, i.e. 
somewhere between heterochromatin and euchromatin. Integration into this 
locus causes intermediate accessibility of transcription factors to activate the 
actin promoter and the cells display a stochastic expression pattern. Therefore, if 
more examination confirms that this integration site is an intermediate locus 
where even one copy of integrated transgene leads to focal but strong 
expression, it will provide an appropriate target site to introduce foreign genes 
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that causes stochastic gene expression in mouse models via site-directed 
integration of a transgene (Bronson, 1996; Misra, 2002).  
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Possible complication due to multi-copy integration of floxed 
transgene. When transgenes more than one copy are integrated into the same 
chromosome, unwanted long chromosomal regions could be deleted and this 
would make the data interpretation harder. 
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The Z-MYC transgenic mouse lines described herein have several 
advantages over other transgenic mouse models where expression of c-MYC 
was driven directly by tissue-specific promoters (Ellwood-Yen, 2003; Zhang, 
2000a). First, the high levels of expression of c-MYC driven by CMV enhancer/β-
actin promoter will approximate the high levels of gene expression in cancers 
and their pathological status. Second, it will allow examination of the effects of c-
MYC overexpression on the response of specific tissue to hormone withdrawal, 
for example, androgen withdrawal, because once activated by Cre recombination, 
the transgene will be under the control of actin promoter and not affected by 
hormone withdrawal. Third, it will provide the wider research community with a 
valuable resource since it can be used in conjunction with other tissue-specific 
Cre mouse lines to activate c-MYC in any tissue of interest, singly or in 
combination with floxed allele of TSGs. 
 More importantly, these Z-MYC mice show stochastic expression of 
transgene although the degree of stochasticity varies depending on tissue types. 
As discussed in CHAPTER III, human cancers are thought to initiate from one 
mutation in a single cell or a few cells. In this regard, this mouse line could mimic 
spontaneous focal mutation in c-Myc in any tissue showing mosaic pattern of Z-
MYC expression and help in better understanding of human carcinogenesis 
initiated c-MYC activation. 
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Materials and Methods 
 
Generation of transgenic mice  
Constructs were made using the pCCALL2-IRES-hAP/cg vector (gift of C. Lobe) 
as a backbone. This vector consists of a CMV enhancer/chicken β- actin promoter, 
a loxP-flanked β-geo, triple repeat of the SV40 polyadenylation signal (poly A), 
and β-globin poly-A sequence. To generate the Z-MYC construct, the region from 
the IRES to the β-globin poly-A in pCCALL2-IRES-hAP/cg was replaced with the 
human c-MYC gene from pSVMYC (gift of P. Leder), including exons 2 and 3 
and poly-A site. The Z-MYC vector was linearized and transfected into 129SV/EV 
ES cells. G418 resistant ES cell clones were picked and expanded into duplicate 
96 wells. The duplicate 96 wells were cryopreserved and the ES cell clones in 
culture expanded into 24 wells for DNA isolation and LacZ analysis. Selected 
clones were expanded from the cryopreserved plates and used to generate 
transgenic mice by injection of ES cells into blastocysts. Male chimeras were 
bred with female C57BL/6 mouse to establish transgenic lines. Transgene-
positive mice were identified by both lacZ stain of ear biopsy and PCR of tail 
DNA. The PCR primers used were as follows: 5’-CGA GTC GTA GTC GAG GTC 
ATA-3’ (forward), 5’-TAG TTC TAG CTA GTC TAG GTC GAT-3’ (reverse) for c-
MYC. Z-MYC positive mice were bred with smMHC-Cre mice that express Cre in 
smooth muscle cells (gift of M. Kotlikoff) to generate smMHC-Cre;Z-MYC double 
positive animals. All analyses, including lacZ staining and western blot analyses 
were done using adult mice older than 6 weeks. 
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Prostate cell line transfection and western blot analysis 
RWPE-1 cells were transfected using Fugene 6 transfection reagent (Roche) 
according to manufacture’s protocol. 48 hours later, cell lysates were prepared 
and processed for western blotting using anti-c-Myc antibody (Santa Cruz) as 
described previously (Roh, 2003). 
 
Adenovirus Cre infection  
ES cell clones were expanded further and infected with adenovirus expressing 
Cre (Ad5CMVCre) or GFP control (Ad5CMVEGFP). Briefly, adenoviruses at 100 
MOI were mixed with 1 ml of ES cell medium containing 2% fatal bovine serum, 
added to ES cells, incubated for 12 hours, and cell lysates were prepared for 
western blotting. 
 
LacZ staining 
All the mouse organs were fixed in 2% paraformaldehyde containing 0.2 % 
glutaraldehyde for 4 hours on ice with gentle shaking. After 1-hour fixation, 
tissues were dissected to help penetration of fixative. To inactivate endogenous 
β-gal activity, the tissues were washed three times for 30 min in phosphate-
buffered saline (PBS) (pH 8.6) and then incubated for 1 hour at 50C. After 
cooling to room temperature, tissues were incubated in prestaining solution 
(2mM MgCl2, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6 and 5mM EGTA in PBS) for 1 
hour at room temperature, and then stained with 0.5 mg/ml X-gal in prestaining 
solution for overnight at room temperature. The tissues were washed with PBS, 
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post-fixed in 4% paraformaldehyde in PBS, processed for paraffin embedding, 
and sections were counterstained with nuclear fast red. 
 
Southern blot analysis 
ES cell DNA was digested with Bgl II for Z-MYC and used for southern blot 
analysis according to standard protocols. Normal mouse tail DNA was included 
as a control after spiking with 0, 1, 2, 3, 4, or 5 copies of transgene per genome. 
Probes were 32P-labelled transgene-specific fragments from Z-MYC construct. 
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CHAPTER V 
 
C-MYC AND CELL COMPETITION 
 
Introduction 
 
 As discussed in CHAPTER I, Myc is involved in cell competition by killing 
neighboring “loser” cells during Drosophila development when there are two 
groups of cell populations, one having relatively high levels of Myc protein and 
the other having low levels. According to the lacZ reporter gene expression data 
(Figure 14) in CHAPTER IV, our Z-MYC mice (line 1) display mosaic pattern of 
transgene expression. This suggests that there exist two cell populations in one 
individual animal or even in one tissue at the same time. This characteristic is 
very important in that there are two groups of cells that have high or low c-Myc 
expression at the same time. In addition, these mice are useful for investigating 
spontaneous human cancer development initiated from a single mutation in a few 
cells. Therefore, the mosaic pattern of c-Myc expression allows us to examine 
the idea of cell competition in mammals, which so far has been demonstrated 
only in invertebrates. In this chapter, evidence of c-MYC-mediated cell 
competition in our mouse model will be provided. 
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Results 
 
Generation of PbCre4;Z-MYC mice with focal, prostate-specific c-MYC 
overexpression 
 
 To target focal c-MYC expression specifically in the mouse prostate, we 
used Z-MYC mice (line 1) that carry a single copy transgene in which the CMV 
enhancer/β-actin promoter drives expression of the β-geo gene and a latent c-
MYC transgene (Figure 12, 13 and 18B) (Roh, 2006). Staining for β-
galactosidase confirmed mosaic expression in the prostate epithelium (Figure 14 
and 18A). To induce c-MYC expression focally in the prostate, we crossed Z-
MYC mice to PbCre4 mice (Wu, 2001) which express Cre recombinase in the 
prostatic epithelium (Figure 18B). As expected, human c-MYC transgene mRNA 
expression occurred only in bigenic PbCre4;Z-MYC mouse prostate, not in other 
tissues of this mouse or in Z-MYC mouse tissues examined, which demonstrates 
that c-MYC transgene expression is prostate-specific after Cre excision (Figure 
18C). Then, to analyze protein expression of c-MYC in the prostate, 
immunohistochemistry for c-MYC was performed. Consistent with lacZ 
expression (Figure 14 and 18A), c-Myc protein expression showed a focal 
pattern in the prostate (Figure 18D). 
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Figure 18. Mosaic transgene expression (lacZ or c-Myc) in the transgenic 
mouse prostate. Z-MYC mouse prostate shows mosaic pattern of lacZ reporter 
gene expression (A) and prostate-specific mRNA (C) and protein (D) expression 
of c-Myc after Cre excision. Note that c-MYC expression is directly regulated by 
CMV enhancer/β-actin promoter once Cre recombination occurs (B) and c-Myc 
protein expression is also focal. 
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c-MYC induces proliferation as well as apoptosis in the mouse prostate 
 First, we examined whether transgene c-MYC is functional in the mouse 
prostate. Since c-Myc is known to induce proliferation as well as apoptosis (see 
Biological functions of c-Myc in CHAPTER I), we determined its effects by 
quantitative RT-PCR or immunohistochemistry. To compare proliferation of 
mouse prostate cells between control mice (wild type, PbCre4 or Z-MYC) and 
MYC mice (PbCre4;Z-MYC), we performed qRT-PCR to analyze mRNA 
expression levels of Ki-67, a proliferation marker. MYC mouse prostate showed 
more Ki-67 expression than Z-MYC control prostate (Figure 19A), and this was 
confirmed by immunohistochemistry for Ki-67 protein expression (panel “b” in 
Figure 19A). Increased proliferation in c-MYC-overexpressing prostates was also 
confirmed by double immunohistochemistry for c-Myc and phospho-histone H3, 
another proliferation/mitotic marker. We found that the c-Myc+ cells in the same 
prostatic gland displayed more phospho-histone H3 positivity (Figure 19B) and 
that PbCre4;Z-MYC prostates contained more phospho-histone H3+ cells than 
control prostates (Figure 19C). Next, to determine c-Myc-induced apoptosis, we 
stained for activated caspase 3, an apoptotic marker (Figure 19C) followed by 
quantitation. We also perfomed Terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) assay (Figure 19D) on the control and MYC prostate 
sections. Both methods consistently showed increased apoptosis in the MYC 
prostates. Collectively, c-MYC protein in the PbCre4;Z-MYC mouse prostate is 
functional both as a proliferative agent and an apoptotic agent. 
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Figure 19. c-MYC expression in the PbCre4;Z-MYC prostates causes 
proliferation as well as apoptosis. Quantitative RT-PCR was performed to 
compare mRNA expression levels of human transgene c-MYC using the whole 
RNA isolated from PbCre4;Z-MYC and Z-MYC mouse prostates (Aa) (Error bars: 
standard deviation of triplicate values). This was confirmed by 
immunohistochemistry for Ki-67 protein (green) (Ab). Double 
immunohistochemistry for phospho-histone H3 (pHH3) and c-MYC (B). (C) 
Immunohistochemistry for activated caspase 3 and phospho-histone H3 was 
performed separately on the prostate sections, and the number of cells positive 
for each marker was counted and normalized with the number of total cells 
counted. Numbers in the brackets indicate the number of mice analyzed in each 
group (Error bars: standard deviation of the indicated number of samples). (D) 
TUNEL assay. TUNEL-positive cells and nuclei are stained green and blue, 
respectively. 
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Non-cell-autonomous apoptosis is dominant in mouse and human prostate 
tissues, but its ratio to cell-autonomous apoptosis varies depending on the type 
of human tissues 
 
 Although PbCre4;Z-MYC prostate displayed increased apoptosis, this 
does not necessarily mean that all the apoptoses are cell-autonomous (c-Myc+ 
cells are apoptotic). Non-cell-autonomous apoptosis (c-Myc- cells are apoptotic) 
denotes killing of neighboring “low” c-Myc cells by “high” c-Myc cells - cell death 
by cell competition. Therefore, we performed double immunohistochemistry for c-
MYC and activated Caspase 3 to examine whether the apoptoses are cell-
autonomous or non-cell-autonomous. Interestingly, the majority of apoptotic cells 
were c-MYC-negative (or low c-MYC) cells and the frequency of apoptosis was 
dramatically decreased the farther away from high c-MYC cells (Figure 20). In 
other words, low c-MYC cells located right next to high c-Myc cells were highly 
apoptotic but cells farther away were the least apoptotic. It also should be 
pointed out that cell-autonomous apoptosis of high c-Myc cells was relatively less 
frequent than non-cell-autonomous apoptosis. 
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Figure 20. Non-cell-autonomous apoptoses in PbCre4;Z-MYC mouse 
prostate. Double immunohistochemistry was performed for c-MYC and activated 
caspase 3. White arrows and a yellow arrow indicate non-cell-autonomous 
apoptoses (red cells) and a cell-autonomous apoptosis (red+green cell), 
respectively (A-F). The number of apoptosis in either c-MYC-positive or -negative 
cells was counted and the apoptotic frequency depending on the distance from c-
MYC-positive cells was analyzed (G). “0” denotes the position of c-MYC positive 
cells. 
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 To test this phenomenon of non-cell-autonomous apoptosis in in vitro cell 
culture, we generated a c-MYC-overexpressing and vector control RWPE-1 cell 
line, a benign human prostate cell line using a lentiviral gene delivery system. 
Since the original FM-1 vector does not have an antibiotic resistance marker, we 
could not select cells that express infected vectors. Therefore, we regarded each 
pooled population with FM-1/control or FM-1/c-MYC plasmid as low c-MYC 
(YFP+) + low c-MYC (YFP-) (L+L) or high c-MYC (YFP+) + low c-MYC (YFP-) 
(H+L) population, respectively. FM-1 vector has a YFP reporter gene, so we 
could track high c-MYC cells in FM-1/c-MYC-infected pooled cell population 
(H+L) and low c-MYC cells in FM-1/control-infected pooled cell population (L+L). 
We cultured the cells without growth factors to induce apoptosis and analyzed 
cell-autonomous (CAA) and non-cell-autonomous apoptosis (NCAA) by 
immunocytochemistry for activated CASPASE 3. When we compared YFP+ and 
YFP- apoptotic cells between L+L and H+L cell population, we observed an 
increase in both CAA (YFP+CASP3+) and NCAA (YFP-CASP3+) in H+L 
population, but apoptoses of YFP+CASP3+ and YFP-CASP3+ were rarely 
changed in L+L population (Figure 21), even after 72-hour growth factor 
starvation. This suggested that c-MYC induced both CAA of c-MYC+ cells and 
NCAA of c-MYC- cells. Previously, it has been shown that conditioned media 
(CM) from the co-culture of high dMyc and low dMyc Drosophila cells induced 
apoptosis of low dMyc cells, but not that of high dMyc cells, suggesting that 
mixed soluble factors released from both high and low dMyc cells kill low dMyc 
cells in vitro (Senoo-Matsuda, 2007). To test this in our RWPE-1 human cell line, 
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we first sorted pooled cell populations to get pure c-MYC+ (high c-MYC) or 
control (low c-MYC) cells. 28.9% of cells in L+L (FM-1/control) population were 
selected for YFP+ low c-MYC cells (YFP+/c-MYC-) and 10% of cells in H+L (FM-
1/c-MYC) population were selected for YFP+ high c-MYC cells (YFP+/c-MYC+) 
(Figure 22A). Conditioned media from two pooled populations (L+L or H+L) were 
then added to each sorted target cells. Interestingly, CM from high and low c-
MYC cell population (H+L) dramatically elevated apoptosis in low c-MYC cells 
(black bars in left panel of Figure 22B) but relatively much less in high c-MYC 
cells (black bars in right panel of Figure 22B). CM from low c-MYC cells (L+L) 
caused minimal apoptosis both in low c-MYC and high c-MYC target cells (white 
bars in Figure 22B). Taken together, c-Myc-induced cell competition may occur in 
mammalian cells and soluble factors from both high and low c-Myc cells may 
enable killing of low c-Myc cells. 
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Figure 21. Analysis of in vitro c-MYC-induced apoptosis in co-culture 
condition. Pooled cell populations were starved for indicated time to induce 
apoptosis and immunocytochemistry was performed for activated CASPASE 3. 
(A) represents cell-autonomous (yellow arrows) and non-cell-autonomous 
apoptoses (white arrows). CASPASE 3 and nuclei were stained red and blue, 
respectively followed by quantitation (B). Error bars = standard deviation. *P < 
0.02, **P < 0.002. 
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Figure 22. Analysis of in vitro c-MYC-induced apoptosis with conditioned 
media using sorted target cells. Both pooled cell populations were sorted to 
get pure YFP+/c-MYC- cells (28.9% in FM-1/control population) and YFP+/c-
MYC+ cells (10% in FM-1/c-MYC population) (A). Conditioned media from FM-
1/c-MYC-infected pooled cell population (H+L) or FM-1/control-infected pooled 
cell population (L+L) were added to sorted target cells (YFP+/c-MYC- cells from 
FM-1/control population or YFP+/c-MYC+ cells from FM-1/c-MYC population) 
and analyzed apoptosis following immunocytochemistry for activated CASPASE 
3. Shown is the quantitated data (B). *P<0.05, **P<0.005. 
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 To confirm that there is increased NCAA in low c-MYC cells near high c-
MYC cells in the human prostate tissues, we did double immunostains for c-MYC 
and activated CASPASE 3 in human prostate cancer specimens. Consistent with 
mouse and in vitro data, low c-MYC cells around high c-MYC cells were highly 
apoptotic, demonstrating a similar pattern of CAA and NCAA shown in PbCre4;Z-
MYC mouse prostates (Figure 23). Next, we examined if c-MYC-induced NCAA 
is dominant over CAA in other human tissues. We stained for c-MYC and 
activated CASPASE 3 in other human cancer specimens. Interestingly, the ratio 
of NCAA over CA was clearly varied depending on tissue types (Figure 24). 
Prostate and rectum, for example, displayed the most frequent NCAA, as 
compared to other tissues. All of the prostate and rectum tissue samples 
analyzed and judged c-MYC+ showed more than 50% NCAA (i.e. less than 50% 
CAA). However, NCAA in colon and lung tissues displayed a wide range, varying 
between 0 to 100%. This suggests that cell types might be a critical factor to 
determine cell competition caused by c-MYC expression. 
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Figure 23. Non-cell-autonomous apoptoses in human prostate cancer 
specimens. Double immunohistochemistry was performed for c-MYC and 
activated CASPASE 3. Arrows indicate non-cell-autonomous apoptoses (A-F). 
The number of apoptosis in either c-MYC-positive or -negative cells was counted 
and the apoptotic frequency depending on the distance from c-MYC-positive cells 
was analyzed (G). “0” denotes the position of c-MYC positive cells. N=8 human 
prostate cancer specimens were analyzed. 
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 Figure 24. Comparison of NCAA and CAA in various human tissues. Human 
tissue microarray sample containing human prostate, colon, rectum, breast and 
lung cancer specimens was subjected to immunostain for c-MYC and activated 
CASPASE 3. Both NCA and CA apoptosis were counted and % NCAA of each 
sample was quantitated (B). Note that prostate and rectum tissues show the 
most frequent % NCAA, and colon and lung tissues show various frequency of 
NCAA (0-100%). Numbers in the brackets indicate the number of tissue samples 
analyzed. (A) represents examples of NCAA in  rectum (most frequent NCAA) 
and lung (rare NCAA) tissues. 
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Discussion and Future Directions 
 
 Cell competition was first shown in Drosophila studies and our data 
suggest that active cell death of “losers” with low c-Myc caused by “winner” cells 
with high c-Myc may also happen in mammalian tissues. Although the data seem 
promising, critical questions still remain to be answered. c-Myc is a labile protein 
known to have a relatively rapid turn-over rate (half-life is about 20-40 mintues 
(Hann, 1984)), so it is important to show that the c-Myc protein is not degraded 
when cells are apoptotic in the prostate. To overcome this problem, other 
transcription factors, e.g. androgen receptor, alternatively can be labeled with an 
apoptotic marker to evaluate the integrity of nuclear proteins when cells undergo 
apoptosis. If not degraded dramatically, it will be more conclusive that non-cell-
autonomous apoptosis occurs in low c-Myc cells, not in high c-Myc cells whose 
c-Myc proteins were degraded due to cell death. This problem can also be 
overcome with in vitro cell culture experiments. Senoo-Matsuda et al. showed 
that low dMyc cells become apoptotic by culturing two types of cells (high and 
low dMyc cells) separately in transwell plates when soluble factors released from 
each group of cells mix, excluding any possibility that cell-autonomous apoptosis 
was due to c-Myc degradation. Other data to consider are that the human tissues 
used here were all cancer samples, so it is possible that genetic alterations other 
than c-MYC may have already occurred. Therefore, additional genetic mutations 
could possibly have caused non-cell-autonomous apoptosis requiring more 
examination in the future to exclude this possibility. 
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 A model has been proposed that is involved in dMyc-induced cell 
competition in Drosophila development. Myc is known to increase ribosomal 
activity by elevating transcription of ribosomal components (Arabi, 2005; 
Eisenman, 2001; Gomez-Roman, 2003; Grandori, 2005; Grewal, 2005; Hulf, 
2005; Levens, 2003; Orian, 2003). When there is a loss of function mutation in 
dMyc (low Myc), the mutant cells lose ribosomal activity and have impaired ability 
to transduce the morphogen Decapentaplegic (Dpp) signals. Due to reduced Dpp 
signaling, the mutant cells are either eliminated through apoptotic program 
(activation of Jnk pathway or Hid gene) or release growth factors like Dpp or 
Wingless (Wg) to stimulate compensatory proliferation of neighboring high Myc 
cells (Gallant, 2005). Therefore, it would be interesting to search for the link 
between non-cell-autonomous apoptosis and activated Jnk pathway through Tgf-
β signaling to demonstrate c-Myc-induced cell competition in mammals because 
Dpp is Tgf-β family member in Drosophila. In addition to Myc, the Warts-Hippo 
pathway was recently shown to cause cell competition in Drosophila (Tyler, 
2007). This pathway is also known as a tumor suppressor pathway and deletion 
of its mouse homologue (Lats 1) induces cancers in mice (Pan, 2007). 
Drosophila cells with mutation in this pathway have been shown to become 
“super-competitors” by killing neighboring wild type cells (Tyler, 2007). 
 The complete pathway analyses have not been elucidated yet, but 
accumulating data and ideas lead to a correlation between cell competition and 
carcinogenesis (Baker, 2008; Moreno, 2008). Since many tumors are found 
genetically heterogeneous, interactions between mutant cells and wild type cells 
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may cause cell competition and the surviving “winner” cells outgrow the other 
cells to be tumorigenic. In this sense, our c-Myc transgenic mice with focal c-
MYC expression should be an important model to correlate cell competition and 
prostate carcinogenesis. 
 
 
 
 104
Materials and Methods 
Animals 
Z-MYC and PbCre4 mice have been described (Roh, 2006; Wu, 2001). Female 
Z-MYC mice (B6/129) were bred to male PbCre4 mice (B6) obtained from 
MMHCC, Frederick, to generate PbCre4;Z-MYC offspring and littermate controls. 
Animal care and experiments were carried out according to the protocols 
approved by the Institutional Animal Care and Use Committees at Vanderbilt 
University. 
 
LacZ stain 
β-galactosidase staining followed by counterstaining with nuclear fast red was 
performed as described (Roh, 2006). 
 
RNA isolation and quantitative RT-PCR 
Total RNA was extracted from mouse tissues according to routine protocol with 
TriZol (Invitrogen). 1µg of RNA was used to synthesize cDNA from reverse 
transcription. Reagents used for reverse transcription were 5X First Strand Buffer, 
dithiothreitol (DTT), M-MLV reverse transcriptase (Invitrogen), RNase inhibitor, 
oligo dT, random hexamer and dNTPs mixture (Promega).  
Real time quantitative PCR reaction was run in Taqman gene amplifying system 
(Applied Biosystems), using SYBR Green 2X master mix (Applied Biosystems) 
after reverse transcription reaction. Primers used were: 
ACCACCAGCAGCGACTCTGA for forward primer of human c-MYC, 
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TCCAGCAGAAGGTGATCCAGACT for reverse primer of human c-MYC, 
CAAAAGGCGAAGTGGAGCTT for forward primer of murine Ki-67, 
GGAGGGACATGTTTCGCAACT for reverse primer of murine Ki-67, 
CATGGCCTTCCGTGTTCCTA for forward primer of murine Glyseraldehyde-3-
phosphate dehydrogenase (Gapdh), and GCGGCACGTCAGATCCA for reverse 
primer of murine Gapdh. The quantity of c-MYC and Ki-67 in triplicate samples 
was normalized with that of Gapdh. 
 
Histology and immunohistochemistry 
Tissues were prepared for histopathological analyses as described (Abdulkadir, 
2001). Human tissue microarrays were purchased from US Biomax, Inc. 
Immunohistochemical analyses were performed as described (Abdulkadir, 2001). 
The following antibodies were used, in some cases with Tyramide Signal 
Amplification (TSA; Perkin Elmer): anti-activated Caspase 3 (rabbit, 1:500, Cell 
Signaling), anti-phospho-histone H3 (rabbit, 1:500, Upstate), anti-c-MYC (rabbit, 
1:15,000 with TSA, Santa Cruz) and anti-Ki-67 (rabbit, 1:50, abcam). For double 
immunofluorescenct stains, c-MYC detected by 1st primary antibody was 
amplified by TSA system (green, Fluorescein). Alexa Fluor 594 (red)-labeled 2nd 
secondary antibody (Molecular Probes) was used to detect 2nd primary 
antibodies (anti-phospho-histone H3 and anti-activated Caspase 3). Nuclear 
stain (DAPI) and sample mounting were performed using Vectashield mounting 
medium (Vector Laboratories).  
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TUNEL assay 
In situ cell death detection kit was purchased from Roche Applied Science and 
TUNEL assay was performed to label apoptotic cells, referring to manufacturer’s 
instruction manual. 
 
Cell lines 
RWPE-1, benign human prostate epithelial cell line (ATCC) was cultured in 
keratinocyte serum-free media supplemented with bovine pituitary extract and 
EGF (Invitrogen). We used lentiviral-mediated gene transfer to generate c-MYC 
overexpressing cells. 293FT packaging cells were plated on 10cm culture dishes 
and transfected with the FM-1/control or FM-1/c-MYC plasmid along with 
vesicular stomatitis virus glycoprotein (VSVG) envelope plasmid and delta 8.9 
packaging plasmid to produce lentivirus. The FM-1 vector was obtained from J. 
Milbrandt (Araki, 2004) and was used to clone in human c-MYC cDNA. Three 
days after transfection, medium containing viral particles was collected and 
added to RWPE-1 for infection with polybrene (8µg/ml). 24 hours post infection, 
medium was changed. YFP+/c-MYC+ or YFP+/c-MYC- control cells were sorted 
by flow cytometry. 
 
In vitro cell competition analysis 
Coverslips were placed on the 24-well plates and 2-300,000 cells were plated on 
the coverslips and incubated under normal condition. For co-culture of pooled 
cell populations, media were changed to supplement-free media to induce 
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apoptosis. After 24, 48 or 72 hours, media were discarded and 
immunocytochemistry was performed for activated CASPASE 3. For conditioned 
media experiments, each pooled cell population was cultured in 10cm dishes 
under supplement-free media for 72 hours and the media were collected. 
Conditioned media were then added back to either sorted YFP+/c-MYC+ cells or 
YFP+/c-MYC- cells plated on the coverslips in the 24-well plates and incubated 
for 4, 10 or 24 hours. Immunocytochemistry was performed for activated 
CASPASE 3 after media were removed. Apoptosis was quantitated from triplicate 
data per group. 
 
Statistical analyses 
We compared groups by using t-test. Values were considered statistically 
significant at P < 0.05. Quantitative variables were expressed as means + SD 
while categorical variables were expressed as numbers (%). 
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CHAPTER VI 
 
MODELING PROSTATE CANCER USING TRANSGENIC MICE WITH 
PROSTATE CELLS WITH DISTINCT MUTATIONS IN C-MYC AND PTEN 
 
 
[This part is adapted from {Kim, J., Eltoum, I.E., Roh, M., Wang, J., Abdulkadir, 
S.A., PLoS Genetics (2009)}] 
 
Introduction 
 
 Prevailing models of multi-step carcinogenesis posit that oncogenic 
mutations arise in isolated cells in situ followed by clonal expansion. This implies 
that important competitive interactions occur between mutant and normal cells as 
well as between cells with distinct oncogenic mutations during tumorigenesis. A 
detailed understanding of these interactions will further efforts aimed at 
therapeutic targeting of neoplastic and preneoplastic lesions. However, these 
interactions have not been well studied in vivo due to a paucity of appropriate 
models. We report here our attempt to model these interactions in a new 
transgenic model of prostate cancer, focusing on the oncogene c-MYC and the 
tumor suppressor Pten (Phosphatase and tensin homologue), both of which are 
implicated in human prostate tumorigenesis (Tomlins, 2006). c-MYC 
overexpression is a common early event in prostate cancer (Ellwood-Yen, 2003; 
Gurel, 2008) while PTEN is deleted/mutated in ~30% of primary human prostate 
cancers (Dahia, 2000; Li, 1997; McMenamin, 1999; Sellers, 2002; Steck, 1997). 
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As discussed in CHAPTER II, previous attempts at modeling c-MYC 
overexpression in the mouse prostate have used prostate-specific promoters that 
target transgene expression to a majority of the cells in the prostatic epithelium. 
Depending on the strength of the promoter used, this resulted in various grades 
of mouse prostatic intraepithelial neoplasia (mPIN) or adenocarcinoma (Ellwood-
Yen, 2003; Zhang, 2000b). Similarly, Pten-mutant mice develop mPIN and 
prostate cancer (Chen, 2005; Ma, 2005; Ratnacaram, 2008; Wang, 2003) and 
Pten inactivation can cooperate with mutations in oncogenes and tumor 
suppressors in prostate tumorigenesis, including p27Kip1 (Di Cristofano, 2001; 
Kim, 2002), Trp53 (Chen, 2005) and Fgf8b (Zhong, 2006).  
To model the sporadic genetic alterations that are thought to occur during 
human somatic tumorigenesis (Fearon, 1990), we previously generated a 
transgenic mouse in which a latent c-MYC transgene can be focally activated in 
the prostatic epithelium by Cre expression (CHAPTER IV). We have also deleted 
one or both copies of Pten in the prostate concurrently with focal c-MYC 
overexpression, in order to examine the interactions of cell populations with 
distinct mutations within the same gland. 
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Results 
 
PbCre4;Z-MYC mice with focal, prostate-specific and androgen-independent c-
MYC overexpression  
 
 We previously generated Z-MYC transgenic mice (CHAPTER IV) and let 
them overexpress c-MYC in a focal, prostate-specific manner by crossing to 
PbCre4 mice (CHAPTER V), in contrast to past models showing uniform c-Myc 
expression in the mouse prostate epithelium (Figure 25). To determine what type 
of cells overexpresses c-MYC in the prostate, the bigenic PbCre4;Z-MYC mouse 
prostate samples were subjected to immunostain for c-MYC in combination with 
either cytokeratin 8 (CK8, a prostate luminal epithelial cell marker) or p63 (a 
basal cell marker). Our results show that c-MYC is focally expressed in CK8+ 
prostate luminal epithelial cells but not p63+ basal cells (Figure 26C). 
Furthermore, c-MYC expression is not abrogated in castrated animals indicating 
that the use of the CMV enhancer/β-actin promoter in our model has uncoupled 
prostate-specific expression from androgen-dependent gene regulation (Figure 
26B). 
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Figure 25. Uniform expression of c-MYC in the Probasin-c-MYC mouse 
prostates. Probasin-c-MYC prostatic intraepithelial neoplasia sample (Ellwood-
Yen, 2003) was stained for c-MYC. Nuclei were stained blue. In contrast to our 
PbCre4;Z-MYC mouse prostates, this line shows uniform expression of c-MYC 
transgene. 
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Figure 26. Focal and androgen-independent c-MYC expression in PbCre4;Z-
MYC mouse prostate epithelial cells. (A) Immunostaining displays sporadic c-
MYC expression in PbCre4;Z-MYC prostate epithelium 17 weeks after castration. 
(B) c-MYC colocalizes with cytokeratin 8 (CK8) (a) but not with p63 (b) in 
PbCre4;Z-MYC mouse prostates. 
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Mild pathology due to focal c-MYC overexpression  
 Focal c-MYC activation resulted in mild pathology, with most prostates 
showing normal histology or low grade mPIN (LGPIN) lesions up to 2 years of 
age (Figure 27A and 27B). This is unlikely due to low level c-MYC expression as 
the CMV enhancer/β-actin promoter is known to drive high level transgene 
expression. A closer examination of the c-MYC expression pattern in the 
prostates of PbCre4;Z-MYC mice with no pathology showed that in young mice, 
the frequency of c-MYC-positive cells was ~18% of the epithelial cells in c-MYC-
positive glands (Figure 28G), evocative of the frequency of lacZ-positive cells 
(~17%) in Z-MYC prostates (Figure 26A). By 1 year, the frequency of c-MYC 
positive cells has increased to ~43% (Figure 28G). The lack of discernible 
histological abnormality in the prostates of a large fraction of older PbCre4;Z-
MYC mice in the face of abundant c-MYC expression is reminiscent of the 
phenomenon of “field cancerization” in human tumorigenesis where incipient 
mutant cells occupy tissue fields without any apparent pathology (Figure 28A-F) 
(Slaughter, 1953). These histologically normal but mutant cells may serve as 
targets for transformation with additional genetic mutations. 
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Figure 27. Pathology of PbCre4;Z-MYC and compound c-MYC/Pten mutant 
mice. (A) H&E-stained prostate sections were analyzed and the summary of the 
pathological grading is shown. (N, number of mice analyzed). (B) Representative 
images of H&E-stained sections show benign glands in control (a), focal LGPIN 
in PbCre4;Z-MYC (boxed region in b and higher magnification in c), focal HGPIN 
lesion in PbCre4;Z-MYC (d), benign glands in PbCre4;Ptenf/+ (e), focal HGPIN 
lesions in PbCre4;Z-MYC;Ptenf/+ (boxed region in f and higher magnification in g) 
and focal micro-invasive cancer lesion (arrow) in PbCre4;Z-MYC;Ptenf/+ (h). 
Scale bars: 100µm in a, b, e and f, and 50µm in c, d, g and h. (C) c-MYC and 
smooth muscle actin (SMA) staining. Arrows in “c” indicate focal areas of 
disruption of SMA (micro-invasion) in PbCre4;Z-MYC;Ptenf/+ prostate. Scale bar: 
100µm. 
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Figure 28. Time-dependent increase of c-MYC-expressing cells without 
discernible histopathology in a subset of PbCre4;Z-MYC mice. (A-C) H&E 
images demonstrate absence of histopathological abnormalities in PbCre4;Z-
MYC prostates at various ages. (D-F) Adjacent sections subject to 
immunofluorescent staining for c-MYC demonstrate the numbers of c-MYC-
overexpressing cells increase in a time-dependent manner. (G) The number of c-
MYC-positive cells in any c-MYC-positive gland was quantitated based on the 
immunostaining shown in D-F. N = 3-4 prostate samples per group. *P<0.05. 
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Focal c-MYC expression cooperates with Pten heterozygosity  
 Next, we generated compound mutant mice with prostate-specific deletion 
of one or both alleles of Pten, concurrently with focal activation of c-MYC. 
Examination of PbCre4;Z-MYC;Ptenf/+ prostates revealed clear cooperation 
between c-MYC overexpression and Pten heterozygosity (Figure 27). As 
reported previously (Ma, 2005; Wang, 2003) and confirmed by us here, 
conditional deletion of a single Pten allele had minimal effects on the prostate, 
with mice up to 50 weeks of age showing no abnormalities (Figure 27A and 27B). 
By 10 weeks of age, however, PbCre4;Z-MYC;Ptenf/+ mice already have 
evidence of focal HGPIN lesions. Over time, these animals develop micro-
invasive cancer as confirmed by the presence of areas with disruption in smooth 
muscle actin (SMA) immunoreactivity (Figure 27B and 27C). We used 
immunohistochemistry to examine the status of the wild type Pten allele in the 
HGPIN/cancer lesions in PbCre4;Z-MYC;Ptenf/+ mice. Consistently, all lesions 
examined (N=8 mice) showed loss of Pten protein expression and 
phosphorylation of its downstream signaling components Akt and Foxo1 (Huang, 
2007) (Figure 29).  
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Figure 29. Focal loss of Pten expression in PIN lesions of PbCre4;Z-
MYC;Ptenf/+ mouse prostate. Immunohistochemistry for Pten, phospho-Akt, and 
phospho-Foxo1 was performed in the adjacent serial sections of PbCre4;Z-
MYC;Ptenf/+ mouse prostate. In focal PIN lesion (arrows), Pten protein 
expression is lost and phosphorylation of Akt and Foxo1 increased, both of which 
are known to be phosphorylated when Pten is lost. 
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c-MYC+;Pten-null cells outcompete Pten-null cells in the same glands  
 We analyzed proliferation by staining for phospho-histone H3, a mitotic 
marker. Proliferation was increased significantly in PbCre4;Z-MYC prostates 
relative to controls, and Pten heterozygosity synergistically increased it further 
(Figure 30A). The proliferation rates in PbCre4;Ptenf/f and PbCre4;Z-MYC;Ptenf/f 
were similarly elevated. However, the focal nature of c-MYC expression in our 
model means that analysis of total proliferation in the PbCre4;Z-MYC;Ptenf/f 
prostates may not be an accurate measure of the proliferation in foci of c-
MYC+;Pten-null cells.  To overcome this, we performed double staining for c-
MYC and phospho-histone H3. As shown in Figure 30B, double mutant (c-
MYC+;Pten-null) cells were more proliferative than single mutant (Pten-null) cells 
within the same prostate glands. Furthermore, double mutant cells were 
histologically distinct from adjacent single mutant cells. The double mutant cells 
were of higher pathological grade with larger nuclei, high nuclear:cytoplasmic 
ratios, hyperchromatic nuclei with prominent chromocenters, focal chromatin 
clearing and prominent single or sometimes multiple nucleoli (Figure 30C and 
Figure 31). In addition, apoptotic and mitotic figures were prominent. Single 
mutant (Pten-null) cells on the other hand showed low nuclear grade with 
comparatively small and uniform nuclei, abundant pale cytoplasm and low 
nuclear:cytoplasmic ratios. These cells also have inconspicuous nucleoli and the 
chromatin is comparatively fine (Figure 30C). These observations suggest that c-
MYC+;Pten-null cells may out-compete Pten-null cells within the same prostate 
gland over time. Indeed, analysis of PbCre4;Z-MYC;Ptenf/f animals showed that 
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at early ages, c-MYC expression was focal within glands, but in older mice, 
lesions showed uniform c-MYC expression, suggesting clonal expansion of c-
MYC-positive cells in a time-dependent manner (Figure 30D). 
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Figure 30. c-MYC expression increases the proliferation and tumorigenicity 
of Pten-deficient cells. (A) Proliferation was determined by analysis of phospho-
histone H3 staining. (B) Phospho-histone H3 index in c-MYC-positive or c-MYC-
negative cells in PbCre4;Z-MYC;Ptenf/f prostates. Inset: double staining shows 
colocalization of phospho-histone H3 with c-MYC in PbCre4;Z-MYC;Ptenf/f 
prostate. N=3-4 mice per group. *p<0.05, **p<0.005, ****p<0.01. (C) c-MYC 
staining identifies MYC-expressing cells next to MYC-negative cells in the same 
gland of PbCre4;Z-MYC;Ptenf/f mouse prostate. An adjacent H&E-stained section 
is also shown. Note distinct, higher grade pathology of c-MYC+ cells. Scale bar: 
50µm. (D) c-MYC+;Pten-null cells outcompete Pten-null cells. Prostates from a 
10 week and 28 week old PbCre4;Z-MYC;Ptenf/f mice were stained for c-MYC 
and smooth muscle actin. At 10 weeks c-MYC expression is focal; at 28 weeks it 
is uniform. Arrows indicate discontinuity of smooth muscle actin (focal micro-
invasion). Scale bar: 100µm. 
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Figure 31. Histopathology of PbCre4;Ptenf/f and PbCre4;Z-MYC;Ptenf/f 
tumors at different ages. PbCre4;Z-MYC;Ptenf/f mice show higher grade lesions. 
Scale bars: 100µm (50µm in insets: higher magnifications). 
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Pten loss does not protect c-MYC overexpressing prostate cells from apoptosis  
 Analysis of apoptosis by staining for activated Caspase 3 showed that 
control and PbCre4;Ptenf/+ prostates had low levels of apoptosis, consistent with 
their normal histology, while focal expression of c-MYC in PbCre4;Z-MYC 
prostates modestly increased apoptosis (Figure 32A). Although c-MYC 
overexpression is known to induce apoptosis in several tissues, this depends on 
many variables including the level of c-MYC overexpression and the “tissue 
context” (Murphy, 2008; Pelengaris, 2002a). The levels of apoptosis seen in 
PbCre4;Z-MYC prostates were consistent with increased cell turnover due to 
enhanced proliferation. Pten-null prostates also had increased rates of apoptosis, 
and c-MYC overexpression further enhanced this effect (Figure 32A). These 
results were surprising as Pten loss is known to activate pro-survival pathways. 
Therefore, we sought to determine if apoptosis was increased in HGPIN/cancer 
cells that had lost Pten expression in our PbCre4;Z-MYC;Ptenf/+ mice. Double 
staining for Pten and activated Caspase-3 and quantitative analysis indicated 
higher rates of apoptosis in Pten-negative cells compared to Pten-positive cells 
(Figure 32B). Thus, Pten loss does not protect prostate cells from apoptosis due 
to c-MYC overexpression. 
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Figure 32. Analysis of apoptosis in c-MYC/Pten compound mutant mice. (A) 
Apoptosis was analyzed by staining for activated Caspase 3. (B) Sections from 
PbCre4;Z-MYC;Ptenf/+ prostates were doubly stained for activated Caspase 3 
and Pten, and the number of apoptotic cells was quantitated in Pten-positive and 
Pten-negative epithelial cells. N=3-4 mice per group. *P<0.05, **P<0.005, 
***P<0.001 and ****P<0.01. 
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  In addition to Akt, the c-Jun N-terminal kinase (Jnk) pathway is known to 
be activated in Pten-deficient cells and tumors (Vivanco, 2007; Yang, 2006). We 
confirmed that the Jnk pathway is activated in both Pten-null and c-MYC-
overexpressing/Pten-null prostates by immunohistochemistry for phospho-Jnk 
(Figure 33A). Since Jnk is well known to have the ability to activate apoptosis, 
cell survival and proliferation, depending on cellular signal stimuli and cellular 
contexts (Bode, 2007), we asked if increased Jnk activity sensitizes Pten-
deficient cells to apoptosis. We used small hairpin RNA to stably downregulate 
PTEN in the benign human prostatic cell line RWPE-1. However, treatment with 
the Jnk inhibitor (SP600125) led to an increase in apoptosis in PTEN knockdown 
cells in a dose-dependent manner, suggesting that PTEN loss-induced Jnk 
activity is anti-apoptotic, rather than pro-apoptotic (Figure 33).  
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Figure 33. Jnk is activated in Pten-deficient cells and is anti-apoptotic. (A) 
Immunohistochemistry for phospho-Jnk demonstrates apparent Jnk activation in 
PbCre4;Ptenf/f and PbCre4;Z-MYC;Ptenf/f prostates (brown). (B) Apoptosis 
increases in Pten-knockdown RWPE-1 cells when treated with Jnk inhibitor 
(SP600125). (C) Western blots show that Pten knockdown is efficient in PTEN-
shRNA-infected RWPE-1 cells. Immunofluorescence images represent increased 
apoptosis in PTEN-knockdown cells (red, activated Caspase 3). Nuclei were 
stained blue. *P<0.01. 
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c-MYC shifts the p53 response in Pten-deficient prostate cells from senescence 
to apoptosis 
 
 Pten loss has been reported to activate the p53 pathway, leading to 
senescence (Chen, 2005; Kim, 2007; Nogueira, 2008). Activation of p53 may 
lead to cell cycle arrest or apoptosis depending on the downstream target genes 
induced (i.e. cell cycle arrest genes such as p21cip1 versus apoptotic genes such 
as PUMA). We therefore asked if activation of the p53 pathway occurs in our 
Pten-null model and whether this sensitizes the cells to apoptosis based on the 
target genes induced.  We observed induction of p53, its targets p21cip1 and 
PUMA in Pten-null prostates (Figure 34A). However, while p53 and PUMA were 
induced in c-MYC-overexpressing Pten-null prostates, p21cip1 expression was not 
(Figure 34A), consistent with the notion that c-MYC represses p21cip1 expression 
(Seoane, 2002). Similar results were obtained in RWPE-1 cells (Figure 34B). 
While p53 and p21cip1 were induced with PTEN knockdown, c-MYC 
overexpression repressed p21cip1 expression (Figure 34B). We hypothesized that 
in Pten-deficient cells with activation of the p53 pathway, repression of p21cip1 by 
c-MYC may switch the senescent response to apoptosis. Indeed, using 
immunofluorescence, we found that in PbCre4;Z-MYC;Ptenf/f prostates, p16ink4a 
expression (a marker of senescence) was mainly localized to c-MYC-negative 
cells, while apoptosis (activated Caspase 3) was found predominantly among c-
MYC-positive cells (Figure 34C). Thus, Pten-deficiency activates the p53/p21cip1 
pathway, but concurrent c-MYC overexpression shifts the output of the pathway 
from senescence to apoptosis, at least partly by repressing p21cip1. 
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Figure 34. c-MYC and p53 pathway status in c-MYC/Pten mutant prostate 
cells. (A) Immunohistochemistry for p53, p21 and Puma. Prostate sections from 
mice of the indicated genotypes were stained with the indicated antibodies and 
nuclei were counterstained with hematoxylin. Positive cells (brown) are indicated 
by red arrows. (B) Western blots show expression of the indicated proteins in 
RWPE-1 cells expressing c-MYC, PTEN knockdown, or control vectors (FM-1, 
pLKO.1). PTEN and phospho-Akt (pAkt) blots confirm efficiency of PTEN 
knockdown. (C) Double immunofluorescent stains for c-MYC/p16 and c-
MYC/activated Caspase 3 in PbCre4;Z-MYC;Ptenf/f prostates. Scale bar: 100µm. 
(D) Model of interactions between c-MYC and Pten with the p53 pathway in c-
MYC-initiated prostate cancer. Focal c-MYC overexpression leads to LGPIN and 
facilitates loss of Pten leading to HGPIN/invasive cancer. Activation of the p53 
pathway due to Pten loss could lead to senescence or apoptosis. c-MYC 
expression is proposed to shift this response towards apoptosis by repressing 
p21 expression. 
 
 
 
 
 
Concurrent c-MYC overexpression and loss of PTEN expression are correlated 
with higher Gleason grades in human prostate cancer  
 
 We used immunostaining to look for cooperativity between c-MYC and 
PTEN in human prostate carcinogenesis. As depicted in Figure 35, 22.4% of the 
58 human prostate cancer samples examined exhibited concurrent c-MYC 
overexpression and reduced PTEN expression, and these samples had 
significantly higher Gleason grades. We also noted some focal PIN lesions that 
display concurrent c-MYC overexpression and loss of PTEN expression (panel c, 
c’ and c” in Figure 35A), reminiscent of the HGPIN lesions in our PbCre4;Z-
MYC;Ptenf/+ mice. 
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Figure 35. Immunohistochemical analysis of c-MYC and PTEN in human 
prostate cancer specimens. (A) Human prostate cancer with (a, a’ and a”) or 
without (b, b’ and b”) c-MYC overexpression and PTEN loss. Isolated PTEN 
(green) expression seen in a’ is due to stromal PTEN expression. Panels c, c’ 
and c’’ show focal PIN lesions with concurrent c-MYC overexpression and PTEN 
loss (arrows). Scale bars: 100µm (B) Venn diagram showing incidence of c-MYC 
expression and PTEN loss in 58 human tumors (C) Correlation between c-
MYC/PTEN status and Gleason grade. c-MYC+;PTEN- status is significantly 
associated with higher Gleason grades (P<0.01). 
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Discussion 
 
 Human prostate carcinogenesis is focal, random, and incremental, but 
current mouse models do not faithfully recapitulate this. Consequently, the 
competitive/cooperative interactions that may occur between mutant and normal 
cells during the early stages of tumorigenesis have not been well studied. The 
model described here exploits the stochastic expression of a “Cre-activatable” c-
MYC transgene (Z-MYC) to induce c-MYC expression in isolated cells 
surrounded by normal cells. As illustrated by our studies when the Z-MYC mouse 
is crossed with prostate-specific Pten deletion, the focal nature of c-MYC 
expression allows analysis of cell populations with different genetic alterations 
within the same prostate gland.  
Our studies have yielded several insights. First, focal expression of c-MYC 
in prostate luminal epithelial cells, even though driven by the CMV enhancer/β-
actin promoter, results in remarkably mild pathology with many mice showing 
histologically normal prostates and a subset of mice demonstrating LGPIN 
lesions. These results imply a remarkable tolerance of luminal epithelial cells to 
c-MYC expression. We showed that the acquisition of additional genetic 
mutations is essential for the appearance of discernable pathology by the fact 
that introduction of Pten heterozygosity into these animals resulted in 
cooperativity, with the development of HGPIN/cancer lesions which in all cases 
were associated with loss of Pten protein expression from the wild type allele. 
These observations highlight an important point about c-MYC-expressing cells in 
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histologically “normal” glands, as may occur in tumors and tissues with “field 
cancerization” (Almadori, 2004; Braakhuis, 2003; Chandran, 2005; Grizzi, 2006; 
Slaughter, 1953) in that the overexpression of c-MYC in histologically “normal” 
cells may facilitate the acquisition of secondary mutations. Although it remains to 
be established whether loss of Pten expression is due to genetic, epigenetic or 
post-transcriptional control, c-MYC expression may facilitate acquisition of 
secondary mutations by increasing cell turnover and/or genomic instability 
(Felsher, 1999; Neiman, 2008).  
Our PbCre4;Z-MYC;Ptenf/f mice allowed us to examine the behavior of 
prostate cells with distinct mutations in the same prostate. c-MYC expression 
clearly confers an additional proliferative advantage to Pten-null prostate cells, 
allowing c-MYC+;Pten-null cells to outcompete Pten-null cells. However, Pten 
deficiency did not alleviate apoptosis in c-MYC+;Pten-null cells. This may appear 
surprising in light of the well-known, pro-survival effect of Pten loss (Suzuki, 
2003) and a report that Pten loss decreased the apoptosis engendered by the 
inactivation of retinoblastoma (pRb) family proteins by a truncated SV40 T large 
antigen in the mouse prostate (Hill, 2005). Nevertheless, previous studies of mice 
with conditional deletion of Pten in the prostate and testicular germline cells have 
noted an increased rate of apoptosis upon Pten deletion (Kimura, 2003; Ma, 
2005; Wang, 2003) and Radziszewska et al recently showed that deleting Pten 
concurrently with c-MYC activation in pancreatic beta cells led to increased 
apoptosis (Radziszewska, 2009). Furthermore, Pten deficiency has been 
reported to activate the p53 pathway leading to senescence (Chen, 2005; Kim, 
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2007; Miyauchi, 2004) as well as to sensitize cells to ROS-induced apoptosis 
(Nogueira, 2008). 
Based on our studies and published reports, we propose the following 
model of cooperativity between c-MYC and Pten in prostate cancer (Figure 34D): 
Overexpression of c-MYC initiates tumorigenesis by facilitating loss of Pten. The 
latter leads to the activation of the p53 pathway, which can result in either 
senescence or apoptosis depending on the predominant Trp53 target genes 
induced (i.e. cell cycle arrest genes e.g. p21cip1 versus pro-apoptotic genes e.g. 
PUMA, Bax etc.). The expression of c-MYC drives cells down the apoptotic 
pathway as it selectively represses the cell cycle arrest-inducing target gene 
p21cip1.  
To summarize, we report a new Cre-dependent prostate cancer mouse 
model that reflects the focal, random and incremental nature of human prostate 
carcinogenesis. We show that focal c-MYC expression cooperates with Pten 
heterozygosity to promote tumor progression due to the selection of cells with 
loss of Pten expression. In addition, cells mutant for both c-MYC and Pten 
outcompete single Pten-mutant cells within the same prostates although Pten-
deficiency sensitizes cells to apoptosis that is associated with activation of the 
p53 pathway and exacerbated by c-MYC expression. Our results highlight the 
utility of modeling focal oncogene activation to study the interactions between cell 
populations with different genetic alterations in tumorigenesis. 
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Implications 
 As discussed earlier in CHAPTER III, introduction of genetic mosaicism in 
model animals is very important and one of the great concerns in modeling 
human somatic genetic diseases. In addition to the methods to induce focal 
genetic mutations discussed in CHAPTER III, our mice can be utilized as a new 
cancer model initiated by focal c-MYC activation. In contrast to previous Pb- and 
ARR2Pb-MYC mouse models which display uniform expression c-MYC (Figure 
25), PbCre4;Z-MYC mice show entire stages of multi-step prostate cancer 
development mimicking human cancer development (Figure 4). They first show 
cancer initiation by focal c-MYC mutation in a few cells, i.e. ~18% of epithelial 
cells in any c-MYC+ prostate gland. Then, the c-MYC mutant cells expand to 
form uniform genetic mutation in prostate glands with time (Figure 28). To avoid 
any possibility that the Z-MYC construct itself caused cell proliferation by 
displaying expansion of mutant cells shown in Figure 28, it needs to be proven 
that the number of cells with β-galactosidase activity in Z-MYC prostates is not 
significantly changed with time, although it is highly unlikely. c-MYC mutation 
alone was not enough to cause invasive cancer, but it led to an “expanding field” 
which did not exhibit histologically visible abnormalities in a subset of PbCre4;Z-
MYC mice. However, with a second mutation in Pten, the compound mutant mice 
developed invasive carcinoma, showing dramatic cooperation between c-Myc 
and either heterozygous or homozygous Pten deletion. 
 The theory of “field cancerization” was first proposed by Slaughter et al. in 
1953 to explain initiation and development of neoplastic and premalignant lesions 
 134
in the oral cavity (Slaughter, 1953). With the recent hypotheses of monoclonal 
origin of cancer and multi-step carcinogenesis (Fearon, 1990), a new model for 
field cancerization has arisen. A genetically altered cell has growth advantages, 
proliferating and displacing normal cells through clonal expansion. This 
“expanding field” is macroscopically normal tissue but has sub-sufficient (some 
but not enough) genetic alterations to develop cancers (Almadori, 2004; 
Braakhuis, 2005; Braakhuis, 2003), (Grizzi, 2006). Interestingly, when 
macroscopically normal tissues adjacent to tumors and actual cancer biopsies 
were analyzed in head and neck squamous cell carcinoma (HNSCC) and breast 
cancer, 36% (10/28) and 26.7% (8/30) of the patient samples have at least one 
loss of heterozygosity (LOH) in putative tumor suppressor loci which are lost 
frequently in HNSCC (Figure 36) and breast cancer, respectively (Deng, 1996; 
Tabor, 2001). In addition, Chandran et al. (Chandran, 2005) confirmed this in 
prostate tissues by comparing genetic expression changes in normal tissues 
from tumor-free donors, normal-looking tissues adjacent to tumors, and tumor 
samples using microarray analysis. Thus, data suggest that there exist normal-
looking “fields” with genetic abnormalities. In this regard, our c-MYC transgenic 
model (PbCre4;Z-MYC) displayed gradual displacement of normal cells with c-
Myc mutant cells, but the “expanding field” included pathologically normal areas, 
which is reminiscent of field cancerization (Figure 28 and 36). Moreover, in terms 
of tumor recurrence, this theory of field cancerization has a crucial implication. 
“Expanding field” in the surgically un-excised tissues which are pathologically 
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normal still has genetic alterations, and the potential to develop primary tumor 
when additional hits of mutations occur (Tabor, 2001). 
 Thus, based on basic concepts of multi-step carcinogenesis and field 
cancerization, our murine prostate cancer model could be a valuable source to 
help understand basic human cancer biology in terms of initiation, progression, 
maintenance and even tumor recurrence in particular by breeding it to other 
mouse models with genetic alterations which confer additional mutations. 
 
 
 
 
 
 
 
Figure 36. Model of field cancerization in head and neck squamous cell 
carcinoma (HNSCC). In normal tissues, cells form a “patch” (clonal unit) when 
there is focal mutation (loss of chromosomal locus 17p). With additional 
mutation(s), a “patch” becomes a “field” showing uniform genetic mutations 
without histologically discernable pathology. However, this normal-looking “field” 
gets cancerous with next oncogenic mutation(s). Chromosomal loci in the ovals 
indicate deletion mutation occurred at each stage. [Adapted from (Braakhuis, 
2003)] 
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Materials and Methods 
 
Animals 
Z-MYC, PBCre4 and Ptenf/f mice have been described (Groszer, 2001; Roh, 
2006; Wu, 2001). The generation of PbCre4;Z-MYC bigenic mice have been 
described (CHAPTER V). To generate compound mutant mice, we generated 
PbCre4;Ptenf/+ males and Z-MYC;Ptenf/+ females which were further bred to 
obtain PbCre4;Z-MYC, PbCre4;Ptenf/f, PbCre4;Z-MYC;Ptenf/+ and PbCre4;Z-
MYC;Ptenf/f offspring for experiments as well as their littermate controls. Animal 
care and experiments were carried out according to the protocols approved by 
the Institutional Animal Care and Use Committees at Vanderbilt University. 
 
Histology and immunohistochemistry 
Tissues were prepared for histopathological analysis as described (Abdulkadir, 
2001), and slides were reviewed by IEA based on published criteria (Mentor-
Marcel, 2001). Human prostate cancer tissue microarrays were purchased from 
US Biomax, Inc. Immunohistochemical analyses were performed as described 
(Abdulkadir, 2001). The following antibodies were used, in some cases with 
Tyramide Signal Amplification (TSA, Perkin Elmer): anti-activated Caspase 3 
(rabbit, 1:500, Cell Signaling), anti-phospho-histone H3 (rabbit, 1:500, Upstate), 
anti-phospho-Akt (rabbit, 1:100, Cell Signaling), anti-phospho-Foxo1 (rabbit, 1:50, 
Santa Cruz), anti-c-MYC (rabbit, 1:15,000 with TSA, Santa Cruz), anti-Pten 
(rabbit, 1:200 with TSA, Cell Signaling), anti-cytokeratin 8 (mouse, 1:2000, 
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Sigma), anti-p63 (PIN Cocktail, Biocare Medical), anti-p53 (rabbit, 1:5000 with 
TSA, Santa Cruz), anti-p21 (mouse, 1:50, Santa Cruz), anti-smooth muscle actin 
(mouse, 1:2000, Sigma), anti-p16 (rabbit, 1:1000, Santa Cruz), anti-phospho-Jnk 
(mouse, 1:100, Cell Signaling) and anti-Puma (rabbit, 1:200, Cell Signaling). For 
double immunofluorescenct stains, c-MYC or Pten detected by 1st primary 
antibodies were amplified by TSA system (green, Fluorescein). Alexa Fluor 594 
(red)-labeled 2nd secondary antibodies (Molecular Probes) were used to detect 
2nd primary antibodies (anti-cytokeratin 8, anti-p63, anti-smooth muscle actin, 
anti-phospho-histone H3, anti-p16 and anti-activated Caspase 3). Nuclear stain 
(DAPI) and sample mounting were performed using Vectashield mounting 
medium (Vector Laboratories).  
 
Proliferation and apoptosis assay 
At least 500 cells per sample were counted and quantitated after 
immunohistochemistry for phospho-Histone H3 and activated Caspase 3. N = 3-4 
prostate samples from 10-15 week-old mice per group. 
 
Cell lines 
RWPE-1 cell culture and c-MYC-overexpressing RWPE-1 cells have been 
described in CHAPTER V. To generate PTEN knockdown cells, we used 
lentiviral-mediated gene delivery system which has been summarized in 
CHAPTER V. PTEN shRNA construct and pLKO.1 vector control were obtained 
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from Sigma. 24 hours post infection, medium was changed and another 24 hours 
later puromycin (1µg/ml) was added for selection of sh-Pten/pLKO.1 cells.  
 
Western blot analyses 
These were performed as described (Roh, 2005) using the following antibodies: 
anti-Pten (mouse, 1:1000, Cell signaling), anti-phospho-Akt (rabbit, 1:2000, Cell 
signaling), anti-total Akt (rabbit, 1:2000, Cell signaling), anti-c-MYC (mouse, 
1:500, Santa Cruz), anti-p53 (mouse, 1:1000, Santa Cruz), anti-p21(mouse, 
1:1000, Santa Cruz) and anti-β-actin antibody (goat, 1:1000, Santa Cruz). 
 
Jnk inhibitor treatment and immunocytochemistry for activated Caspase 3 
Coverslips were placed in the 24-well plates and 300,000 control or Pten 
knockdown RWPE-1 cells were plated on the coverslips. Next day, cells were 
treated with the Jnk inhibitor (SP600125) or vehicle (DMSO) at 0, 10 or 50µM for 
one hour. Then cells were washed with phosphate-buffered saline (PBS) and 
supplement-free medium was added to induce apoptosis. After 48 hours, 
immunocytochemistry for activated Caspase 3 was performed and apoptosis was 
quantitated from triplicate data per group. 
 
Statistical analyses 
We compared groups by using t-test or Chi-square test (Preacher, 2001) 
(http://www.quantpsy.org). Values were considered statistically significant at P < 
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0.05. Quantitative variables were expressed as means + SD while categorical 
variables were expressed as numbers (%). 
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CHAPTER VII 
 
FUTURE DIRECTIONS AND OVERALL CONCLUSIONS 
 
Future Directions 
 
 We have examined prostate cancer progression using transgenic mice 
with distinct mutations in c-Myc and Pten and observed interactions between 
single mutant cells (Pten-null) and double mutant cells (c-Myc+;Pten-null) 
followed by expansion of the latter in the same prostatic glands. Next question is 
what would be the next favorable mutation to facilitate prostate tumor 
progression, since mutations in c-Myc and Pten encounter p53-dependent 
biological barriers to overcome (Figure 34). In addition, c-Myc mutation in Pten-
deficient cells switched the p53 response from cellular senescence to apoptosis, 
with an increase of apoptosis in double mutant cells (c-Myc+;Pten-null) in 
comparison to single mutant cells (Pten-null). Interestingly, we noticed poorly 
differentiated cancer development with a dramatic decrease of apoptosis in the 
prostates of old PbCre4;Z-MYC;Ptenf/f mice (~30 weeks) (data not shown) which 
showed well differentiated cancer with elevated apoptosis at younger ages (10-
15 weeks). This is probably an indication of suppression in p53 activity as a third 
mutation to progress from micro-invasive cancer to advanced cancer due to 
either p53 deletion or inactivation of p53 expression. We will be examining p53 
expression in these old mouse (PbCre4;Z-MYC;Ptenf/f) prostates and possible 
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loss of p53 gene locus in the focal areas showing poorly differentiated carcinoma 
by laser-captured microdissection (LCM). 
 Previously, it has been shown that p53 deficiency alone does not cause 
histological abnormalities in mouse prostates (Chen, 2005). To elucidate further 
the cooperation between mutations in c-Myc and p53, we generated PbCre4;Z-
MYC;p53f/+ and PbCre4;Z-MYC;p53f/f mice by breeding PbCre4;Z-MYC mice to 
p53-floxed mice (Jonkers, 2001) and observed focal HGPIN/prostate cancer 
development in  both lines (Figure 37). This reflects obvious cooperation 
between mutations in c-Myc and p53 based on mild phenotype of PbCre4;Z-MYC 
prostates and lack of pathological phenotype in p53-deficient prostates. 
 
 
 
 
 
 
Figure 37. Focal microinvasive cancer in PbCre4;Z-MYC;p53f/f mouse 
prostate. Shown is 34-week old mouse prostate displaying microinvasion 
(arrows) at focal area. Scale bars: 100µm. 
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As discussed in CHAPTER I, one of c-Myc-dependent apoptosis pathways is 
through p53 activity. Since c-Myc activates p19ARF expression which inhibits 
MDM2 E3 ligase, p53 protein is stabilized and induces p53-dependent apoptosis 
(Zindy, 1998). We have seen that c-Myc-overexpressing mouse prostate cells 
showed increased apoptosis (Figure 32) and this is probably due to p53 
activation. We monitored p53 activation with c-MYC overexpression in human 
prostate cell line (3rd lane in Figure 34B), and in the future we will test this by 
immunostaining p53 protein in the prostate sections of PbCre4;Z-MYC, 
PbCre4;Z-MYC;p53f/f and PbCre4;Z-MYC;p53f/+ mice. 
 In addition, utilizing the focal nature of our mouse prostate will provide 
information which will compare genetic profiles between cell populations with 
distinct mutations in the same prostate (Figure 38). We should perform laser-
captured microdissection (LCM) from formalin-fixed paraffin-embedded (FFPE) 
tissues and isolate RNA followed by RNA amplification. This protocol is very 
challenging because RNA extracted from FFPE tissues is susceptible to 
degradation and being cross-linked to protein (RNA-protein) or to RNA (RNA-
RNA) due to formalin fixation. RNA isolation yield is generally low and cross-
linked RNA does not serve as a good enzymatic substrate for traditional 
microarray platforms (Abramovitz, 2008; Bibikova, 2004; Cronin, 2004; Godfrey, 
2000; Masuda, 1999). Since the purpose of this is to compare genetic profiles 
between focal areas (Figure 38), expected isolated RNA amount will be small, 
which contributes to the difficulty. We initially tried to optimize the protocol and 
analyzed RNA quality isolated from the FFPE tissues (Figure 39). Fortunately, 
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we got promising results for RNA quality and amount that could be used for 
microarray analysis (sample #3 in lane 4 in Figure 39A and 39B). After more 
optimization followed by genetic profile analysis, we expect to see signaling 
differences between two cell populations, such as p53 target gene expression 
(either senescence- or apoptosis-inducers). 
 
 
 
 
Figure 38. Tissue microdissection from PbCre4;Z-MYC and PbCre4;Z-
MYC;Ptenf/f mouse prostate sections. Laser-captured microdissection will be 
performed on weakly hematoxylin-stained sections (top) to take two distinct cell 
populations (wild type/c-Myc+ OR Pten-/c-Myc+;Pten-) based on c-Myc 
immunostaining (bottom). 
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Figure 39. RNA isolation from FFPE tissues and quality analysis. RNA 
samples extracted from FFPE tissues were subjected to electrophoresis on 
bioanalyzer to analyze RNA quality. (A) lane 0 and 1 indicate size marker (size in 
nucleotides), lane 2-4 are isolated RNA samples (sample #1-#3, respectively) 
and lane 5 is an 18S/28S ribosomal RNA (rRNA) standard. (B) demonstrates an 
electropherogram of sample #3 in lane 4 in (A). Sample #3 shows enough 
amount and quality for microarray analysis (concentration: 9.8ng/ul; absorbance 
ratio (A260/A280): 1.35; rRNA ratio (28S:18S): 1.7; RNA Integrity Number (RIN): 
9.3) 
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 Lastly, the transgenic mice described herein are self-controlled mouse 
models, meaning that we can analyze the effect of one mutation by comparing 
two cell populations consisting of wild type/c-Myc+ cells or Pten-/c-Myc;Pten- 
cells in one animal. Once we get gene expression profile data, we may be able to 
identify some differences in specific signaling pathways or gene expression 
profiles between two groups of cells with distinct mutations. We can then 
compare cell fate changes depending on drug susceptibility between control 
groups (wild type or Pten- cells) and positive groups (c-Myc+ or c-Myc+;Pten- 
cells, respectively) in the same prostate of one mouse after the mouse has been 
treated with drugs that inhibit specific signaling pathways (e.g. mitogen-activated 
protein kinase (MAPK) or PI3 kinase (PI3K) inhibitors) or suppress general 
cancer effects, like increased reactive oxygen species (ROS) (Nyska, 2003; Tam, 
2006). 
 146
Overall Conclusions 
 
 Based on the theories of multi-step carcinogenesis and field cancerization 
(Fearon, 1990; Slaughter, 1953), human somatic cancers are thought to initiate 
from an oncogenic mutation either in an oncogene or in a tumor suppressor gene 
in a single or a few cells (Figure 40A and 40B). This single mutation is normally 
not enough to lead to cancer development because the mutated cells often 
encounter barriers, such as cell-cycle arrest (senescence) or apoptosis (Figure 
40B’). Depending on the strength of the mutation, the mutant cells stop 
proliferating until there is an additional mutation or they expand clonally without 
displaying histological abnormalities (“field”) (Figure 40C). At this stage, the 
mutant cells are sub-sufficient to be cancerous, but have more of a potential to 
be malignant than completely normal un-mutated cells. When that next hit that 
suppresses the barriers comes, the cells start to develop lesions with histological 
abnormalities (Figure 40D), which ultimately progress to carcinoma (Figure 40E). 
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Figure 40. Model of multi-step carcinogenesis and field cancerization. When 
a normal cell is mutated (A and B), it is either eliminated (B’) or clonally 
expanded to form a “field” (C) which is histologically normal. An additional 
mutation induces abnormal phenotypes (D) and sometimes leads invasive 
cancer development (E) which is more likely pushed by a third oncogenic 
mutation. 
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 Numerous mouse models of human prostate cancer have been generated 
(CHAPTER II) and exhibit common characteristics of human prostate cancer. 
However, most of them may not mimic spontaneous human carcinogenesis 
because of uniform activation of oncogene(s) or inactivation of tumor suppressor 
gene(s) in the majority of prostate cells. Consequently, a lot of efforts have been 
made to model focal the nature of spontaneous cancer initiation using various 
methods (CHAPTER III). Here, we first report on transgenic mice (Z-MYC) that 
can express c-Myc in multiple tissues in a stochastic manner even though the 
rate of mosaicism is varied depending on tissue types (CHAPTER IV). When we 
activated c-Myc specifically in the prostate (PbCre4;Z-MYC mice), we found that 
~18% of prostate epithelial cells in any c-Myc+ gland showed c-Myc 
overexpression at young age. With time, the number of c-Myc mutant cells 
increased and displayed an “expanding field” without abnormal pathology in a 
subset of PbCre4;Z-MYC mice, probably due to a suppressive mechanism. 
When we introduced Pten deletion as a second genetic alteration, however, most 
of the compound mutant mice developed a precursor stage (HGPIN) of prostate 
cancer or invasive carcinoma. Biological barriers were still present in these 
compound mutant mice, but they (PbCre4;Z-MYC;Ptenf/f mice) developed 
advanced, poorly differentiated cancer with time, which was probably due to loss 
of p53 activity as a third mutation. 
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